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The biological response to implanted medical devices is critical to the success of surgical 
procedures. Implantation of foreign devices into the body increases infection risk and may 
cause inflammation, both of which can result in surgical/device failure. Electrospinning is 
a promising manufacturing technology due to its capacity to form medical devices 
composed of nano- and micro-fibers from almost any polymer or polymer/drug 
combination. This versatility allows for tuning of fiber size and selection of polymer and/or 
drug to locally modulate the biological response to devices. Here, we investigate the use of 
electrospinning to manufacture devices with added functionality to improve clinical 
outcomes.  
 
Although they are associated with vision-threatening eye infections, more than 12 million 
nylon sutures are used in ocular procedures each year. We demonstrate manufacture, via 
wet electrospinning, of biocompatible sutures capable of sustained antibiotic release for 
more than 60 days in vitro and activity against Staphylococcus epidermidis for at least 1 
week in vitro.  
 
Next, we engineered a novel system to manufacture and twist together hundreds of drug-
loaded nanofibers into a single multifilament suture. To our knowledge, this is the first 
demonstration of a drug-loaded suture capable of surpassing United States Pharmacopeia 
strength specifications. Multifilament sutures delivered antibiotic at detectable levels in rat 
eyes for at least 14 days, and prevented ocular infection against consecutive bacterial 
inoculations over 1 week in a rat model of bacterial keratitis.  
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Millions of vascular anastomosis procedures are performed yearly. The inflammatory 
response to the surgical procedure using sutures leads to neointimal hyperplasia, and 
resulting vessel stenosis. We demonstrate manufacture of nanofiber-coated sutures capable 
of sustained anti-proliferative drug release and reduction of neointimal hyperplasia, in 
comparison to standard nylon sutures, following anastomosis of the rat abdominal aorta.  
 
Finally, we describe the adaptation of our manufacturing platform to glaucoma, which 
affects over 60 million people, and in which fibrosis is the major cause of surgical treatment 
failure. We demonstrate manufacture of nano-structured, small lumen glaucoma shunts that 
are biocompatible and significantly reduce intraocular pressure in normotensive rabbits for 
at least 27 days. Collectively, these results demonstrate the clinical potential of nano-
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Drug delivery systems (DDS) capable of local and sustained release provide significant 
advantages in the treatment of disease.1 Localized drug delivery has the potential to 
improve treatment efficacy through site-specific administration, while simultaneously 
requiring a lower dose of drug, and reducing systemic side-effects.2 Sustained drug release 
may preclude issues with medication adherence and patient compliance, and minimize 
complications by limiting the number of invasive procedures or injections.1,3 Despite these 
advantages, FDA approval and successful commercialization of DDS is a lengthy and 
capital-intensive process, and remains a major challenge.1,4 Drug-eluting devices are a sub-
category of DDS with reduced commercial risk, as they are often regulated as medical 
devices with a shorter development timeline and approval process than drug products.4 
Thus, medical devices providing local drug delivery in a sustained manner provide a 
promising avenue for improvement of clinical outcomes across a wide range of surgical 
procedures and in the treatment of a variety of diseases. As more therapies utilize devices 
during surgery or indicate implantable devices for treatment, incorporating drug delivery 
functionality can provide significant additional benefit.4 Drug-eluting devices can improve 
patient care through ease of use and therapy compliance, deliver drug locally to eliminate 
the side-effects and risks of systemic exposure, and/or improve the safety and effectiveness 
of an existing device or surgical procedure by modulating the local biological response to 
reduce complications and the need for re-interventions. In the latter case, regulatory 
approval follows a medical device pathway with the existing device as the predicate.4 In 
order to achieve successful clinical translation, drug-eluting devices must be 
biocompatible, stable for the duration of use, cost-effective, and under ideal circumstances, 
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are composed of generally regarded as safe (GRAS) materials, deliver a drug already 
approved for the intended application, fit into the surgical workflow, do not require 
additional maintenance or removal, and are reimbursable.1,4,5  
 
Electrospinning is a promising platform for the manufacture of drug-eluting medical 
devices. Electrospinning is compatible with almost any natural or synthetic polymer, can 
incorporate prophylactic or therapeutic moieties, and be realized into a wide range of 
different morphologies or conformations.6,7 Devices manufactured via electrospinning are 
also highly modifiable through coatings, laser cutting, and other processing modifications 
to tune each aspect of the device, including size, shape, strength, rigidity, porosity, 
degradability, glidability, and biocompatibility. Moreover, the capacity of electrospinning 
to produce nanofibers and incorporate them into a medical device provides a substantial 
advantage. Kam and coworkers have demonstrated that nanoscale features with high aspect 
ratios decrease expression of growth factors associated with fibrosis.8 They also showed 
that these features can reduce protein adsorption which has been implicated in device 
fouling and can lead to infection or device failure.9 Here, we describe the use of 
electrospinning to manufacture medical devices with potential to improve clinical 
outcomes via nanotopography and/or local drug delivery. 
 
 
Sutures are used ubiquitously in colon and rectal, general, neurological, obstetrics and 
gynecological, ocular, oral and maxillofacial, orthopedic, otolaryngological, plastic, 
thoracic and cardiovascular, and urological surgery.10 The almost universal use of sutures 
at the surgical site makes them well-situated for therapeutic, prophylactic, and/or wound 
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healing interventions. However, attempts to develop drug-eluting sutures have been limited 
primarily by a lack of sufficient tensile strength.7,11-22 Drug-coated sutures have been 
developed to circumvent these shortcomings, but are limited in their capacity to load 
sufficient drug, control drug release, and/or scale manufacturing.14,17,23-27 Without the 
ability to deliver drug in a controlled manner, drug-coated sutures are limited to use in anti-
infection applications in general surgery, and to date, there are no market offerings for 
drug-eluting sutures in ocular or vascular surgery. 
 
Although conventional nylon sutures are associated with vision-threatening microbial 
keratitis and endophthalmitis, they are used in closure of 2 million corneal wounds per year 
in the United States, and in more than 12 million ocular procedures per year globally.28-30 
For this reason, it has become routine to prescribe expensive antibiotic drops off-label for 
prophylactic use after ocular surgery; however, topical eye drops are associated with poor 
patient compliance.31 Additionally, properly instilling eye drops is particularly difficult for 
pediatric patients and for those who are elderly and/or in cognitive decline.32,33 A potential 
alternative to frequent topical application is through antibiotic delivery from the surgical 
suture itself. For this purpose, the suture must: (i) be of suitable size for ocular surgery, (ii) 
be of high-strength to resist breakage and bacterial colonization, and (iii) provide sustained 
antibiotic delivery. Chapter 2 describes the manufacture, via wet electrospinning, and 
evaluation of an absorbable, antibiotic-eluting, monofilament suture for ocular surgery. 
Chapter 3 details the development of a novel manufacturing process for production of 
multifilament, ophthalmic-grade, antibiotic-eluting sutures with improved mechanical 
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properties. Chapter 3 also describes the use of these sutures to prevent infection within a 
rat model of bacterial keratitis.  
 
 
Millions of anastomoses, or surgical connections between arteries or veins, are performed 
in vascular bypass, vascular access, solid organ transplant, and reconstruction procedures 
each year in the United States.34 Neointimal hyperplasia, or proliferation and migration of 
vascular smooth muscles cells into the vessel lumen space, develops immediately post-
operatively at the anastomotic site due to the damage and resulting inflammation caused 
by surgical closure of the anastomosis using sutures.35 The resulting stenosis, or narrowing 
of the vessel after the anastomosis, is the main contributor to arterial, venous, and 
arteriovenous graft failure.36-40 Depending on the type of procedure, failure rates due to 
neointimal hyperplasia have been reported up to 50%.41 Thus, preventing anastomotic 
stenosis is the key to long-term efficacy of all types of vessel anastomoses. We 
hypothesized that a drug-coated suture could modulate the post-operative inflammatory 
response to reduce neointimal hyperplasia while also providing sufficient strength for an 
extended period of time to allow for sufficient wound healing. Chapter 4 describes the use 
of the novel manufacturing process detailed in Chapter 3 to uniformly coat a conventional 
nylon suture with degradable, drug-loaded nanofibers. Chapter 4 also details the use of 
these nanofiber-coated sutures in a rat model of vascular anastomosis. 
 
We also hypothesized that the novel manufacturing platform described in Chapter 3 could 
be extended to the manufacture of a broad range of medical devices to improve outcomes 
in a variety of surgical interventions. Glaucoma is a leading cause of irreversible vision 
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loss that affected over 60 million people in 2010.42,43 It is known that intraocular pressure 
(IOP) reduction prevents development of glaucoma and vision loss from glaucoma.44,45 
While surgery lowers IOP more effectively than eye drop treatment, it is associated with 
reduced visual acuity, increased cataract formation, and perioperative complications such 
as hyphema, ptosis, and hypotony (IOP that is too low), which each occur in approximately 
10% of cases.46 Glaucoma surgeries create a vent for fluid to be released from the eye. This 
vent is either fashioned from the wall of the eye (trabeculectomy) or is created by a 
glaucoma drainage implant (GDI). These surgeries lose efficacy over time, and the five-
year failure rates for trabeculectomy or the Ahmed and Baerveldt® GDIs are 25.7%, 39.5%, 
and 44.7%, respectively.47,48 The majority of surgical failures occur as a result of scar tissue 
and fibrosis around the vent following surgery.49 Alternatively, the surgery can vent 
pressure too well, thereby causing low IOPs. Hypotony can occur after trabeculectomy (up 
to 18%) as well as following insertion of GDIs such as the Ahmed or Baerveldt®.47,50,51 
Thus, glaucoma surgery would be significantly improved by creating a venting system that 
both minimizes the fibrotic response and decreases the risk of post-operative hypotony. 
Chapter 5 describes the adaptation of our novel manufacturing system for production of 
nano-structured glaucoma shunts, and the evaluation of a non-absorbable, small-lumen 
glaucoma shunt in a normotensive rabbit model. 
 
Medical devices are used in almost every surgical procedure, and additional functionality 
via nanotopography and/or local drug delivery can serve to improve therapeutic efficacy 
and/or reduce complications following surgical intervention. The manufacturing platform 
described in Chapters 3-5 can be used to provide controlled drug release functionality to 
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medical devices through direct loading and/or via coating. Moreover, this technology can 
be implemented within the current surgical workflow, preclude issues with patient 
compliance, and incorporate a broad range of drugs for a multitude of clinical applications. 























2. Development of absorbable, antibiotic-eluting sutures for ophthalmic 
surgery 
 
Note: This chapter has been published in Translational Vision & Science Technology in 




Interest in the development of drug-eluting sutures for a variety of clinical applications has 
grown over the past decade.12,17,52 Drug-eluting sutures may prevent complications and/or 
serve in a therapeutic role while simultaneously closing wounds and holding tissue 
together.53 Sutures are already a part of the surgical workflow, and this next generation of 
sutures could provide for additional functionality through local and sustained drug 
release.12 However, attempts to develop drug-eluting sutures have been limited by lack of 
sufficient tensile strength, sustained drug release, or scale needed for commercial 
viability.7,11-22 Furthermore, drug-eluting sutures thin enough to be used in ophthalmic 
surgery have not been described in the literature (Table 2.1.), where, globally, more than 
12 million procedures per year use nylon sutures to close ocular wounds and incisions.30,54-
57 In 2002, Ethicon received approval to market a series of antibiotic-coated sutures; 
however, none are indicated for ophthalmic use and, to date, there are no market offerings 




Although infections of the eye, such as bacterial keratitis and endophthalmitis, are rare, 
they can lead to significant negative consequences including corneal ulceration, edema, 
inflammation, and blindness.61 It has long been reported that the placement of foreign 
material into the body reduces the inoculum size of bacteria required for infection, and that 
the conventional nylon sutures used in ocular procedures can harbor bacteria and 
potentially facilitate infection.28,62 This phenomenon is further exacerbated when sutures 
become loose or break in situ. Heaven and coworkers reported that almost 40% of loose or 
broken nylon corneal sutures were contaminated with bacteria, and Staphylococcus 
epidermidis (S. epidermidis) was isolated in more than 80% of cases.29 For this reason, it 
has become routine to prescribe expensive antibiotic drops off-label for prophylactic use 
after ophthalmic surgery; however, topical eye drops are associated with low patient 
compliance.31 Additionally, properly instilling eye drops is particularly difficult for 
pediatric patients and for those who are elderly and/or in cognitive decline.32,33 A potential 
alternative to frequent topical application would be to supply antibiotics directly from the 
surgical suture itself. For this purpose, the suture must: (i) be of suitable size, (ii) be of 
high-strength to resist breakage and bacterial colonization, and (iii) provide sustained 
antibiotic delivery. Such a suture might prevent ocular infections while providing 
convenience for both the patient and the surgeon.  
 
Here, we describe the development of an absorbable suture loaded with levofloxacin, a 
third-generation fluoroquinolone and broad spectrum antibiotic used to treat ocular 
infection.63,64 The suture was manufactured via electrospinning, a simple technique first 
introduced in the early 1900’s that employs electric forces to elongate and simultaneously 
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decrease the diameter of a viscoelastic polymer stream, allowing for the formation of solid 
fibers ranging from nanometers to microns in diameter.6,65 Electrospinning provides a 
scalable and versatile platform, allowing for the incorporation of almost any polymer, such 
as the poly(L-lactide) (PLLA) and polyethylene glycol (PEG) used in this work. Both of 
these polymers are generally regarded as safe (GRAS) and have been used in medical 
devices approved by the United States Food and Drug Administration.66 We investigate the 
size, strength, drug release, bacterial inhibition, and biocompatibility of this new platform.  
 
2.2. Materials and Methods 
 
2.2.1. Microfiber Suture Fabrication 
Levofloxacin microfiber sutures were manufactured using the wet electrospinning setup 
depicted in Figure 2.1.A and described by Zhang and coworkers.67 Briefly, PLLA (221 
kDa; Corbion, Amsterdam, Netherlands) at 86-89% (w/w) was mixed with levofloxacin 
(Sigma Aldrich, St. Louis, MO) at 10 wt% and either PEG (35 kDa, Sigma Aldrich) or 
Pluronic F127 (BASF, Florham Park, NJ) between 1-4 wt% and dissolved in chloroform 
(Sigma Aldrich) at room temperature for 24 h. Levofloxacin concentration was held 
constant and PLLA concentration in chloroform was maintained at 15 wt% in all 
formulations. Sutures were produced by wet electrospinning the polymer/drug solution in 
a setup consisting of a high voltage power supply (Gamma High Voltage Research, 
Ormond Beach, FL), syringe pump (Fisher Scientific, Waltham, MA), and rotating metal 
collector with hexane (Sigma Aldrich) as the lending solvent. The polymer solution was 
ejected through a blunted 18G needle (Fisher Scientific) at 13 mL/h with 4.7 kV of applied 
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voltage 5 cm away from the collector rotating at 40 rpm. Fibers were then collected and 
desiccated for two days prior to storage at -20⁰C. 
 
2.2.2. Suture Characterization 
 
2.2.2.1. Suture Size and Morphology  
Sutures were serially dehydrated in ethanol (Sigma Aldrich) and dried prior to sputter 
coating with 10 nm of Au/Pd. Samples were then imaged via scanning electron microscopy 
(SEM) at 1-2 kV using a LEO Field Emission SEM (Zeiss, Oberkochen, Germany) and 
suture diameter measured using ImageJ software (n = 14 for each condition). 
 
2.2.2.2. Tensile Strength Measurement 
Mechanical properties of the sutures were evaluated using a DMA 6800 (TA Instruments, 
Timonium, MD). 3 cm long samples (n = 7 for each condition) were clamped vertically 
and force from a 5 N load cell was applied at 0.05 N/min to stretch the sample until 
breaking. 
 
2.2.3. In Vitro Drug Release 
10 mg of suture (n = 3) was placed into 10 mL of 1x Dulbecco’s Phosphate Buffered Saline 
(PBS, ATCC, Manassas, VA) rotating at 37⁰C. At each time point, 2 mL aliquots were 
withdrawn and replaced with fresh PBS. Aliquots were frozen, lyophilized, and 
resuspended in ultrapure water prior to high performance liquid chromatography (HPLC; 
Waters Corporation, Milford, MA) analysis. 100 µL samples were injected into a Waters 
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SymmetryTM 300 C18 5 µm column with a mobile phase of 0.1% v/v trifluoroacetic acid 
(Sigma Aldrich) in water:acetonitrile  (75:25 v/v, Fisher Scientific) at a flow rate 1 mL/min. 
Elution was monitored by a 2998 photodiode array detector to detect levofloxacin with 
excitation at 290 nm and emission at 502 nm. Drug loading was determined by dissolving 
a 5 mg sample of suture into a mixture of tetrahydrofuran (Sigma Aldrich):acetonitrile 
(20:80) and injecting into the column under the same conditions as the release samples.  
 
2.2.4. Assessment of Bacterial Inhibition  
1 cm of suture was placed in 1 mL of PBS and incubated at 37⁰C for 1, 3, and 6 h and 1, 2, 
3, 4, 5, 6, and 7 days (n=6 for each time point). S. epidermidis (ATCC) was cultured 
overnight at 37⁰C on agar plates produced using nutrient agar (BD, Franklin Lakes, NJ). 
At each time point, sutures were retrieved and placed on plated cultures in order to 
investigate bacterial inhibition. Bacterial inhibition zones around the sutures were 
measured and imaged 24 h after suture placement. 
 
2.2.5. Assessment of In Vivo Biocompatibility  
Animals were cared for and experiments conducted in accordance with protocols approved 
by the Animal Care and Use Committee of the Johns Hopkins University. Protocols are 
also in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. 1 mm of 8-0 Ethilon® (nylon), Vicryl® (poly(lactic-co-glycolic acid); 
PLGA) (Ethicon, Somerville, NJ) and 4% PEG/PLLA/levofloxacin sutures (n=3) were 
implanted into the corneas of 6-8 weeks old, male Sprague-Dawley rats (Harlan 
Laboratories, Frederick, MD). Prior to implantation, rats were intraperitoneally 
12 
 
anesthetized with a solution of Ketamine:Xylazine (75:5mg/kg, Sigma Aldrich) and a drop 
of 0.5% proparacaine hydrochloride ophthalmic solution (Bausch & Lomb Inc., Tampa, 
FL) was applied to the cornea. Following implantation, the rats were evaluated for signs of 
infection every day for seven days. The rats were then euthanized and eyes enucleated, 
fixed in formalin (Sigma Aldrich) for 24 h, embedded in paraffin, cross sectioned, and 
stained with hematoxylin and eosin for histological evaluation. 
 
2.2.6. Statistical Analysis 
Suture size, strength, and in vitro drug release are presented as mean ± standard error. 




2.3.1. Suture Fabrication and Characterization 
Several different parameters, including needle gauge, flow rate, applied voltage, distance 
to collector, lending solvent, and collector rotation speed were optimized in order to 
manufacture sutures from a wet electrospinning setup described previously (Figure 
2.1.A).67 Electrospinning of a 10 wt% polymer solution with application of 4.7 kV into a 
collector containing hexane and rotating at 40 rpm allowed for manufacture of a single, 
uniform, defect-free, cylindrical filament without beading, necking, or pores (Figure 
2.1.B), which might adversely affect tensile strength and reproducibility. Microfibers 
manufactured with a collector speed of 40 rpm were thinner than those manufactured at 
lower speeds, and were more uniform in diameter than those manufactured at higher speeds 
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where there was also significant fiber loss at the edge of the collector. PLLA and 
levofloxacin served as the core suture components and the concentration of drug was held 
constant in the various formulations tested; however, the addition of F127 or different 
concentrations of PEG modified several suture properties. 4% PEG along with the use of 
blunted 18G needles and a flow rate of 13 mL/h provided for sutures 45.1 ± 7.7 µm in 
diameter (Figure 2.2.A). This qualifies as an 8-0 suture suitable for use in ophthalmic 
surgery, and would be stronger than 9-0 or 10-0 sized sutures manufactured from this setup. 
Under these conditions, it was possible to produce meters of suture material at a time.  
 
Following suture manufacture, fibers were desiccated and stored at -20⁰C preceding use in 
additional experiments. Prior to tensile testing, sutures were allowed to fully thaw and were 
cut into 3 cm segments. Tensile strength evaluation determined that the 4% 
PEG/PLLA/levofloxacin formulation also provided the highest breaking strength of all 
formulations tested at 0.099 ± 0.007 N. As the concentration of PEG increased from 1% to 
4%, by weight, so did the average strength of the sutures (Figure 2.2.B), although it was 
not statistically significant. 
 
2.3.2. In Vitro Levofloxacin Release 
Preliminary studies indicated minimal drug release from PLLA/levofloxacin sutures 
manufactured via electrospinning. However, the addition of small percentages of F127 and 
PEG polymers to the formulation resulted in significant and sustained release of 
levofloxacin in vitro (Figure 2.2.C). Regardless of the addition to the core polymer 
formulation, all modified suture formulations demonstrated initial burst release in the first 
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48 h followed by a slow, sustained, and linear release prior to ultimately reaching a plateau. 
The 4% PEG/PLLA/levofloxacin suture demonstrated the most significant burst release 
and also the highest cumulative release of all formulations tested. This suture formulation 
was found to have 4% drug loading and levofloxacin was detected in release media after 
more than two months with approximately 65% cumulative release. 
 
2.3.3. Inhibition of S. Epidermidis 
Bacterial inhibition zone experiments were conducted with S. epidermidis to determine 
whether levofloxacin released from sutures was capable of eliminating bacteria in an in 
vitro setting, and how long this effect might last in vivo. 4% PEG/PLLA/levofloxacin 
sutures were cut to 1 cm in length and incubated in 37⁰C PBS from 1 h up to 7 days. After 
each time point, the suture was removed from solution and placed in the center of an agar 
plate that had been cultured with S. epidermidis for 24 h. PBS, neat drug, and 4% 
PEG/PLLA sutures were used as controls (Figure 2.3.A-C). As depicted, PBS, and 4% 
PEG/PLLA did not inhibit bacterial growth, while the 4% PEG/PLLA/levofloxacin suture 
created a 2 cm inhibition zone after 24 h of drug release in PBS. Further, after 7 days in 
release media (Figure 2.3.D), drug-loaded sutures still provided bacterial inhibition, 
confirming that biologically active antibiotic was being released from the suture in an 
amount sufficient to eliminate surrounding bacteria. 
 
2.3.4. In Vivo Performance and Biocompatibility 
In order to evaluate the potential clinical value of an absorbable, antibiotic-eluting suture, 
wet electrospun sutures were implanted into the corneal stroma of male Sprague Dawley 
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rats. 8-0 Ethilon®, 8-0 Vicryl®, and 8-0 4% PEG/PLLA/levofloxacin sutures of 
approximately 1 mm in length were compared to each other and untreated controls after 7 
days. Notably, 4% PEG/PLLA/levofloxacin sutures remained in the cornea and maintained 
integrity through the 7 day period, similar to the Ethilon® and Vicryl® sutures. Rats were 
monitored daily, and there were no gross signs of infection or inflammation among any of 
the animals for all sutures tested. Histological analysis (Figure 2.4.A-D) showed that the 
tissue reaction to the electrospun 4% PEG/PLLA/levofloxacin suture was indistinguishable 
to that of the nylon suture and untreated controls. There were no obvious signs of 
neovascularization or inflammation in the control, nylon, or antibiotic-eluting suture 
conditions. However, immune cell infiltration was apparent in each of the rat eyes 




In this study, we demonstrated the manufacture, via wet electrospinning, of an absorbable, 
antibiotic-eluting suture composed of PLLA, PEG, and levofloxacin. The drug-eluting 
sutures provided sustained antibiotic release for more than 60 days in vitro, demonstrated 
activity against S. epidermidis for at least 1 week in vitro, and demonstrated similar 
biocompatibility to standard nylon sutures when implanted into rat corneas. To our 
knowledge, this is the first study to describe ophthalmic-grade antibiotic-eluting sutures 
prepared by electrospinning. Future studies to further preclinical development will include 
evaluation of duration of in vivo antibiotic release and prevention of ocular infection in 
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vivo using varied suture lengths in the range of lengths typically used for ophthalmic 
procedures (a few mm to several cm).68 
 
Wet electrospinning proved to be a versatile and scalable platform for the manufacture of 
drug-loaded sutures. Filament size was easily modified by changing equipment parameters 
such as flow rate, and a single run was able to manufacture several feet of uniform filament 
material.67 As with other electrospinning setups, the system is compatible with a wide range 
of polymer, drug, and solvent combinations.65 There is potential for this system to be used 
to tune suture size (2-0 to 10-0), degradation time (weeks to years), and drug release (burst 
and/or sustained) to allow for myriad clinical applications.  
 
Similar to previous studies using electrospinning to manufacture drug-eluting sutures, the 
breaking strength of the 8-0 sized 4% PEG/PLLA/levofloxacin was below what is required 
by USP specifications.11,12,15,18,69 Although the suture maintained integrity when implanted 
in vivo, additional optimization to further improve the mechanical properties of electrospun 
sutures is necessary. The literature has shown that voltage and polymer concentration can 
influence PLLA crystallinity and, therefore, breaking strength.70 Additionally, it is possible 
that certain polymer and drug combinations would be stronger than others due to 
physicochemical interactions. Interestingly, although levofloxacin and PLLA are both 
hydrophobic, increasing the concentration of hydrophilic PEG did not significantly modify 
suture tensile strength.66,71 In addition to varying electrospinning parameters and 
modifying polymer/drug choice, electrostretching and other post-modifications may serve 
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to improve tensile strength.67 Residual solvent may also have reduced the tensile strength 
of the sutures.12 
 
While optimizing tensile strength, consideration must be given to maintaining an ideal drug 
release profile. In this study, we observed a burst release in the first 48 h followed by 
sustained release for more than 30 days, which is ideal for eliminating and preventing 
infection. However, increasing the PLLA molecular weight to improve strength may 
further slow the second period of drug release to the point where antibiotic release is below 
the minimum inhibitory concentration. 
 
Of critical importance in this study was the in vivo safety profile of the 4% 
PEG/PLLA/levofloxacin suture. While residual solvent is a concern in the use of 
electrospinning for biomedical applications, there were no signs of local or systemic 
toxicity due to any residual chloroform that may have remained in the suture after 
desiccation. Furthermore, the local inflammation observed via histology was comparable 
to nylon and clearly less than that of commercially available sutures composed of PLGA. 
This may be due to the quicker degradation of PLGA into acidic byproducts.12 PLLA is 
known to be a biodegradable, biocompatible polymer with good crystallinity and strength, 
and has been shown not to elicit negative cellular or tissue reactions in other electrospun 
suture applications.19  
 
Nylon sutures can harbor bacteria and lead to post-operative ocular infections that are 
vision-threatening if not properly cared for. While antibiotic eye drops are effective, they 
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are rarely used as prescribed. Hermann and coworkers observed topical antibiotic eye drop 
compliance in patients following cataract surgery and found that no patient followed the 
protocol exactly. 50% of patients took less than half of the prescribed doses over the course 
of the study.31 Lack of compliance with antibiotic drops may not only allow for an infection 
to occur and to progress, but will also provide for the development of antibiotic 
resistance.72 Ophthalmic-grade sutures capable of sustained antibiotic delivery may 




This study demonstrated the manufacture of an absorbable, ophthalmic-sized suture 
capable of sustained in vitro release of levofloxacin and inhibition of S. epidermidis, a 
common cause of post-operative ocular infection. The suture composed of PLLA, PEG, 
and levofloxacin was histologically similar after implantation in the rat cornea to 
commercially available nylon, whereas Vicryl®, a commercially available, absorbable 
suture composed of PLGA, demonstrated immune cell infiltration. With improved strength, 
this platform has the potential to prevent post-operative infection and preclude issues with 








Table 2.1. United States Pharmacopeia specifications for absorbable sutures. 
Suture size and strength suitable for ophthalmic surgery are highlighted in green.  





























Size Min. Max.   
10-0 20 29 0.24* 
9-0 30 39 0.49* 
8-0 40 49 0.69 
7-0 50 69 1.37 
6-0 70 99 2.45 
5-0 100 149 6.67 
4-0 150 199 9.32 
3-0 200 249 17.4 




Figure 2.1. Wet electrospinning setup and microfiber suture SEM. 
(A) Schematic of wet electrospinning setup. Voltage is applied to the polymer or 
polymer/drug solution which is driven into a rotating, grounded collector containing 
hexane. This provides for the manufacture of (B) long, uniform, defect-free, and drug-








Figure 2.2. Suture diameter, tensile strength, and in vitro drug release. 
Monofilament suture (A) diameter, (B) breaking strength, and (C) in vitro drug release with 
the addition of different polymers to the core PLLA/levofloxacin formulation. 2% F127, 
1% PEG, and 4% PEG suture diameters are suitable for ophthalmic use. ** indicates p < 
0.01. All formulations provide for sutures of similar strength. All formulations demonstrate 
sustained release of levofloxacin, while the 4% PEG formulation provides for a more rapid 




Figure 2.3. In vitro bacterial inhibition. 
Staphylococcus epidermidis cultured on agar plates in the presence of (A) PBS, (B) 4% 
PEG/PLLA suture, (C) 4% PEG/PLLA/levofloxacin suture after 24 h. Black arrow 
indicates suture location. (D) Inhibition zones were measured for sutures bled for up to 1 
week. A bacterial inhibition zone is clearly present surrounding the 4% 
PEG/PLLA/levofloxacin suture after bleeding for 24 h, and the sutures continue to show 
















Figure 2.4. Histological analysis of suture biocompatibility. 
Representative images of hematoxylin and eosin stained sections of (A) untreated corneal 
tissue and tissue surrounding (B) 4% PEG/PLLA/levofloxacin, (C) 8-0 permanent nylon 
(Ethilon®), and (D) 8-0 absorbable PLGA (Vicryl®) sutures following implantation for 1 
week in Sprague-Dawley rat corneas. The electrospun suture elicited a tissue reaction 
comparable to that of nylon, while immune cell infiltration was observed in the vicinity of 












From the first recorded use of natural fibers as sutures in 3,500 B.C. to the advent of 
synthetic, absorbable sutures in 1970, advances in material science and surgical practice 
have sought to develop the perfect suture: one that is sterile, strong, easy to handle, 
absorbable, and biologically inert to provide the appropriate conditions for wound healing 
and tissue repair.18,52,56,73,74 The ideal suture also degrades and loses strength as the 
surrounding tissue heals and gains strength, and is able to scale to commercial production. 
We envision a generation of sutures that will meet each of these requirements while also 
providing sufficient and controlled release of therapeutic moieties, such as small molecule 
drugs, nucleic acids, and proteins to reduce complications and modulate the biological 
response to surgery in order to improve clinical outcomes.  
 
Sutures are a promising means of therapeutic delivery directly to the surgical site. However, 
clinical implementation of such technology has been limited due to the inability of drug-
loaded sutures to meet United States Pharmacopeia (U.S.P.) standards for suture 
strength.57,75 Conventional suture manufacturing processes are not compatible with most 
therapeutic moeities, and drug-loaded sutures in preclinical development have 
demonstrated breaking strength of only one-tenth that the strength required for clinical 
use.11,12,18,20,21,69,75-80 Drug-coated sutures have been developed to circumvent these 
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shortcomings, but are limited in their capacity to load sufficient drug, control drug release, 
and/or scale manufacturing.14,17,23-27 Without the ability to deliver drug in a controlled 
manner, drug-coated sutures are limited to use in anti-infection applications, which are the 
only current market offerings for drug delivery via sutures. However, these antibacterial 
coatings are only available in conjunction with absorbable thread, are only indicated for 
use in general surgery (6-0 – 2-0 U.S.P. classification), and do not meet U.S.P. 
specifications for diameter. 
 
There is a significant need for an antimicrobial suture in ocular surgery, where, globally, 
more than 12 million procedures per year use conventional nylon sutures to close ocular 
wounds and incisions.30 Non-absorbable nylon sutures are a mainstay of ocular surgery due 
to their increased biocompatibility in comparison to absorbable sutures, and their capacity 
to retain strength at the surgical site.66 Nylon sutures are used in procedures such as 
penetrating keratoplasty, where sutures may remain in the eye for 12-24 months, and as 
with other implantable devices, increase the risk of infection following ophthalmic 
procedures due to their susceptibility to bacterial adhesion, proliferation, and biofilm 
formation.28,29,61,81-83 Incidence of infectious keratitis following penetrating keratoplasty 
has been reported between 1.76% and 12.1%.84 Suture-related complications are 
implicated in 20% to more than 50% of these cases, and can have devastating consequences, 
including poor visual outcomes, re-intervention, and graft failure.84-87 Thus, it is 
particularly important to provide for local antibacterial functionality along with 
implantation of non-absorbable sutures within the eye. Local antibiotic delivery from the 
suture itself would provide bacterial inhibition at the vulnerable surgical incision and help 
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to alleviate concerns of non-compliance with topical antibiotic eye drops, which are often 
prescribed post-operatively. Antibiotic-eluting sutures may also reduce the need for post-
operative oral antibiotic prescriptions, the systemic administration of which can lead to 
emergence of resistant organisms and associated complications such as Clostridium 
difficile infection and life-threatening diarrhea.72,88 In addition to keratoplasty, glaucoma, 
retinal detachment, vitrectomy, and cataract surgeries, where nylon sutures have been used, 
antibiotic-eluting sutures may also decrease the risk of infection associated with concurrent 
implantation of keratoprostheses, lacrimal stents, orbital plates, glaucoma drainage 
implants, or other ocular devices.89-96 
 
An antibiotic-eluting suture for ophthalmology must be extremely fine (20 – 50 µm in 
diameter; 10-0 – 8-0 U.S.P. classification) while retaining high strength for the duration of 
the intended application and providing sufficient release of an antibacterial agent to reduce 
or prevent ophthalmic infection.57,75 Here, we describe a novel manufacturing system for 
production of ultra-thin, high strength, antibiotic-loaded sutures for ophthalmic surgery. 
The basis for this platform is a well-known and versatile fiber production technique known 
as electrospinning, which applies high voltage to a polymer solution to draw out fine 
threads.6 Although the use of electrospinning in suture manufacture has been previously 
reported in the literature, to our knowledge, this is the first platform to manufacture and 
twist individual, highly crystalline, drug-loaded nanofibers into a single, multifilament 
suture capable of surpassing U.S.P. strength specifications.11,12,20,69,76 In order to provide 
an antibacterial alternative to the use of nylon sutures in ophthalmic surgery, we 
manufactured sutures composed of 80 kDa polycaprolactone (PCL) and levofloxacin 
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(Levo). Levo is a third-generation fluoroquinolone and broad-spectrum ophthalmic 
antibiotic indicated for treatment of bacterial conjunctivitis.97 PCL is a biocompatible 
polymer capable of long-term degradation that has been used in sutures and other medical 
devices for more than 30 years.66,98-100 We maximized fiber crystallinity, and consequently, 
suture tensile strength by electrospinning nanofibers composed of low molecular weight 
PCL and subsequently twisting them into a single suture to provide additional compaction 
and structural reinforcement. We evaluated antibiotic-eluting suture size, breaking strength, 
drug release, biocompatibility, and efficacy in vivo in a rat model of bacterial keratitis.  
 
3.2. Materials and Methods 
 
3.2.1. Suture Manufacture 
Polymer solutions were made via dissolution of 80 kDa PCL (Sigma-Aldrich, St. Louis, 
MO) alone or with drug in hexafluoroisopropanol (Sigma-Aldrich) by shaking overnight 
at room temperature. PCL concentration was maintained at 10% (w/w) in relation to 
solvent. Levofloxacin (Sigma-Aldrich), moxifloxacin (LKT Laboratories, St. Paul, MN), 
bacitracin (Carbosynth, San Diego, CA), and tobramycin (Sigma-Aldrich) were dissolved 
at either 8%, 16%, 24%, or 40% (w/w) in relation to polymer. Solutions were electrospun 
via pumping at 450 µL/h through a 20 G blunt-tip needle with an applied voltage of 17kV, 
at a distance of 13 cm from a set of parallel grounded collectors to form parallel nanofibers. 
One collector was then rotated clockwise for a specified number of rotations (twists) prior 




3.2.2. Suture Characterization 
 
3.2.2.1. Suture Size  
Suture diameter was determined via light microscopy using the 20x objective of an Eclipse 
TS100 (Nikon Instruments, Melville, NY) and calibrated Spot 5.2 Basic imaging software 
(Spot Imaging, Sterling Heights, MI). Each suture was measured at three different locations 
at least 2 cm apart, and used in additional experimentation only if the average diameter was 
within ± 0.5 µm of the specified diameter.  
  
3.2.2.2. Suture Morphology 
Suture morphology was observed via scanning electron microscopy (SEM) at 1 kV using 
a LEO Field Emission SEM (Zeiss, Oberkochen, Germany). Prior to imaging, samples 
were desiccated and then sputter coated with 10 nm of Au/Pd (Desk II, Denton Vacuum, 
Moorestown, NJ). 
 
3.2.2.3. Suture Breaking Strength  
Sutures (n = 3-4 for each condition) were clamped vertically and then pulled until breaking 
at a rate of 2.26 mm/min using a DMA 6800 (TA Instruments, Timonium, MD). 
 
3.2.2.4. Suture Strength Retention 
PCL/8% Levo and PCL/16% Levo sutures (n = 5) were sectioned into two halves. The 
breaking strength of one segment was measured as described above, while the other 
segment was submerged in 1x Dulbecco’s Phosphate Buffered Saline (PBS; ATCC, 
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Manassas, VA) and shaken at 225 rpm at 37 ⁰C for 31 days. Sutures were then dried prior 
to measuring breaking strength. 
 
3.2.2.5. Suture Drug Loading 
15 mm of PCL/8% Levo and PCL/16% Levo sutures (n = 3) were submerged in a mixture 
of acetonitrile and tetrahydrofuran (80:20, Fisher Scientific, Waltham, MA) and sonicated 
for 30 minutes prior to evaluating via high performance liquid chromatography (HPLC). 
Samples were injected into a SymmetryTM 300 C18 5 µm column (Waters Corporation, 
Milford, MA) with a mobile phase of 0.1% v/v trifluoroacetic acid (Sigma Aldrich) in 
water:acetonitrile (75:25 v/v, Fisher Scientific) at a flow rate of 1 mL/min. Levofloxacin 
was detected at an excitation wavelength of 295 nm and emission wavelength of 496 nm.  
 
3.2.3. Animal Studies 
All animals were cared for and experiments conducted in accordance with protocols 
approved by the Animal Care and Use Committee of the Johns Hopkins University. 
Protocols are also in accordance with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. 
 
3.2.3.1. In Vivo Biocompatibility  
Three 2 mm long 10-0 nylon, Vicryl® (poly(lactic-co-glycolic acid); PLGA) (Ethicon, 
Somerville, NJ) and PCL/Levo suture filaments were implanted into the corneas of 6-8 
week old, male Sprague Dawley rats (Harlan Laboratories, Frederick, MD). Prior to 
implantation, rats were intraperitoneally anesthetized with a solution of ketamine:xylazine 
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(75:5mg/kg, Sigma Aldrich) and a drop of 0.5% proparacaine hydrochloride ophthalmic 
solution (Bausch & Lomb Inc., Tampa, FL) was applied to the cornea. Following 
implantation, the rats were evaluated daily for signs of infection, inflammation, or irritation. 
Two days after implantation, the rats were euthanized and eyes enucleated, fixed in 
formalin (Sigma Aldrich) for 24 h, embedded in paraffin, cross sectioned, and stained with 
hematoxylin and eosin (H&E) for histological evaluation. 
 
3.2.3.2. Pharmacokinetic Study  
PCL/8% Levo and PCL/16% Levo sutures were implanted into Sprague Dawley rat 
corneas as described above (n = 4 for each formulation at each time point). At 15, 60, and 
120 min, and at 1, 3, 7, and 14 days, aqueous humor was collected from each eye, followed 
by removal of implanted sutures and harvesting of the cornea. Tissue and aqueous humor 
samples were weighed immediately after harvesting. Corneal tissue samples were 
homogenized in 100 µL to 150 µL of PBS prior to extraction. The standard curve and 
quality control samples were prepared in PBS as a surrogate matrix for both aqueous humor 
and homogenized tissue. Levofloxacin was extracted from 15 µL of aqueous humor or 
tissue homogenate with 50 µL of acetonitrile containing 1 μg/mL of the internal standard, 
moxifloxacin-d4 (Toronto Research Chemicals, Canada). After centrifugation, the 
supernatant was then transferred into autosampler vials for LCMS/MS analysis. Separation 
was achieved with an Agilent Zorbax XDB-C18 (4.6 × 50 mm, 5 μm) column with 
water/acetonitrile mobile phase (40:60, v:v) containing 0.1% formic acid using isocratic 
flow at 0.3 mL/min for 3 minutes. The column effluent was monitored using an AB Sciex 
triple quadrupole™ 5500 mass-spectrometric detector (Sciex, Foster City, CA) using 
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electrospray ionization operating in positive mode. The spectrometer was programmed to 
monitor the following MRM transitions: 362.0 → 318.0 for levofloxacin and 406.1 → 
108.0 for the internal standard, moxifloxacin-d4. Calibration curves for levofloxacin were 
computed using the area ratio peak of the analysis to the internal standard by using a 
quadratic equation with a 1/x2 weighting function using two different calibration ranges of 
0.25 to 500 ng/mL with dilutions up to 1:10 (v:v) and 5 – 5,000 ng/mL.  
 
3.2.3.3. Bacterial Inoculation and Evaluation 
Sprague Dawley rats were anesthetized as described above. The operative eye was then 
scratched using a 20 G needle (Fisher Scientific) prior to implantation of three 2 mm long 
nylon (n = 12), Vicryl® (n = 4), or PCL/8% Levo (n = 4) suture filaments. 100 µL of 1x108 
CFU/mL of S. aureus was then administered topically over a period of 10 mins. 10 µL of 
0.5% levofloxacin solution was administered topically either once post-operatively or three 
times daily to rat eyes with nylon sutures (n = 4, each). Two days after implantation, gross 
images were taken of each eye, prior to swabbing the cornea with a cotton-tipped applicator 
(Fisher Scientific), and streaking onto tryptic soy agar (Fisher Scientific) plates. Plates 
were stored in an incubator at 37 ⁰C for 24 h and then imaged. After swabbing the eye, eyes 
were enucleated and either prepared for histological evaluation as described above (n = 3 
for each condition) or evaluated for bacterial load (n = 4 for each condition). Briefly, each 
eye was placed in sterile tryptic soy broth (Fisher Scientific) and homogenized using a 
Power Gen 125 homogenizer (Fisher Scientific) for 4 min. Samples were then centrifuged 
at 300 rcf for 5 min, and optical density of the supernatant measured at a wavelength of 
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600 nm via spectrophotometry. Infection was confirmed by a positive swab culture and 
bacterial load significantly higher than a control eye.  
 
A long-term study was also performed to evaluate resistance to infection after multiple 
inoculations. Nylon, PCL/8% Levo, and PCL/16% Levo sutures (n = 8, each) were 
implanted into rat corneas on day 0, with inoculation of S. aureus to only the PCL/Levo 
suture conditions, as described above. On day 2, rat corneas were swabbed to evaluate 
infection. On day 5, the corneas of all rats were scratched and inoculated with S. aureus. 
On day 7, swabs were taken of each cornea followed by either histological evaluation, 
bacterial homogenization, or removal of sutures for examination via SEM (n = 4 for each 
condition). For the latter experiment, sutures were removed from the cornea and fixed in 
formalin (Sigma-Aldrich) for 30 min prior to washing with PBS and dehydration with 
increasing concentrations of ethanol (Fisher Scientific). Sutures were then imaged as 
described above. 
 
3.2.4. Statistical Analysis 
Suture breaking strength, Levo concentration, and bacterial load are presented as mean ± 
standard error. Statistical significance for breaking strength and bacterial load data was 
determined via one-way ANOVA followed by Tukey test. Statistical significance for the 








We hypothesized that sutures composed of twisted PCL/Levo nanofibers would provide 
suitable strength at the surgical site for an extended duration while also delivering antibiotic 
in a sufficient and controlled manner to prevent post-operative suture colonization and 
ocular infection. 
 
3.3.1. Suture Manufacture and Characterization 
In order to limit the effect of drug loading on the strength of polymeric matrices, we 
engineered a novel manufacturing system capable of producing and twisting together 
hundreds of individual drug-loaded, polymeric nanofibers (Figure 3.1.A). As with 
conventional electrospinning, high voltage is applied to a polymer or polymer/drug 
solution pumped at a controlled flow rate in order to form polymeric fibers. However, 
instead of collecting fibers on a rotating drum, fibers are collected in parallel between two 
grounded collectors situated perpendicularly to the syringe pump. Rotation of one collector 
results in the twisting of deposited parallel fibers into a single, multifilament suture. The 
amount of fiber deposition, and consequently, suture diameter can be reproducibly tuned 
by adjusting spray time.  
 
SEM of multifilament sutures confirmed manufacture of a highly uniform, non-porous, and 
defect-free thread composed of nanofibers (Figure 3.1.B). Notably, individual nanofibers 
had a flat, ribbon-shaped morphology. Multifilament, drug-loaded sutures were cylindrical 
in nature and met U.S.P. specifications for 10-0 suture diameter (20-29 µm), making them 
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suitable in size for ocular surgery. They were also comparable in both size and shape to 
commercially available 10-0 Ethilon® (nylon) sutures (Figure 3.1.B).   
 
3.3.2. Suture Breaking Strength 
The key challenge for translation of drug-loaded sutures to the clinic has been an inability 
to meet U.S.P. specifications for suture strength. Thus, we next examined the impact of 
fiber conformation, drug concentration, drug type, and diameter on antibiotic-loaded suture 
breaking strength.  
 
Figure 3.2.A illustrates the difference in PCL suture strength with 8% Levo in either a 
monofilament or twisted multifilament conformation of identical diameter (28 µm). As 
may be expected, monofilament PCL suture breaking strength was reduced by more than 
50% when Levo was incorporated (p < 0.001). In contrast, the multifilament PCL suture 
breaking strength was not significantly changed with drug loading. Further, the 
multifilament PCL suture breaking strength increased accordingly with the increase in 
number of collector rotations (twists). A multifilament PCL suture with 1,575 twists, 8% 
Levo within the suture formulation, and a diameter of 28 µm surpassed the minimum U.S.P. 
breaking strength specification for 10-0-sized sutures of 0.24 N.  
 
Next, we explored the amount of drug that could be loaded into multifilament sutures while 
maintaining U.S.P. strength specifications. We produced 1,575 twist, 28 µm multifilament 
sutures composed of PCL with no drug or with 8%, 16%, 24%, or 40% Levo within the 
suture formulation. Sutures with 16% or more Levo had a significantly lower breaking 
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strength (p < 0.05) than PCL sutures alone or with 8% Levo (Figure 3.2.B). It was possible 
to include up to 24% Levo within the multifilament suture formulation while still 
surpassing clinical strength requirements for a 10-0 suture. Notably, even with inclusion of 
40% Levo into the suture formulation, multifilament PCL suture breaking strength was 
significantly higher (p < 0.05) than a monofilament suture with 8% Levo (Figure 3.2.A), 
and reached 75% of the U.S.P. specification (Figure 3.2.B). Critically, both PCL/8% Levo 
and PCL/16% Levo sutures maintained their strength and demonstrated minimal 
degradation in vitro over a period of 31 days in PBS. 
 
We next evaluated the compatibility of the multifilament suture platform with various types 
of small molecule antibiotics indicated for ophthalmic use. We manufactured 1,575 twist, 
28 µm sutures composed of PCL and 8% of either moxifloxacin, bacitracin, or tobramycin. 
Moxifloxacin is a fourth generation fluoroquinolone that has shown superior potency to 
Levo, while bacitracin and tobramycin are from the polypeptide and aminoglycoside 
antibiotic classes, respectively.72 Although these antibiotics have different 
physicochemical properties owing to their varying molecular structures, there was no 
significant difference in breaking strength of multifilament PCL sutures loaded with any 
of these molecules (Figure 3.2.C). Importantly, all drug-loaded sutures met both size and 
strength specifications for a 10-0 suture for ocular surgery. 
 
9-0 (30-39 µm) and 8-0 (40-49 µm) sutures are also commonly used in ocular surgery. We 
evaluated the capacity for this manufacturing platform to scale to larger diameter sutures 
with correspondingly improved breaking strength by increasing electrospinning spray time 
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to manufacture 1,575 twist PCL/8% Levo sutures that were 38 µm (9-0) and 48 µm (8-0) 
in diameter. In order to understand the effect of suture diameter on breaking strength, we 
also evaluated the breaking strength of 21 µm diameter PCL/8% Levo sutures 
manufactured in a similar fashion (Figure 3.2.D). Varying suture diameter significantly 
affected breaking strength in all cases (p < 0.05). Decreasing suture diameter from 28 to 
21 µm decreased breaking strength more significantly than increasing Levo concentration 
from 8% to 40% (Figure 3.2.B), demonstrating the importance of suture diameter in the 
resulting breaking strength of multifilament sutures. 38 µm PCL/8% Levo multifilament 
sutures surpassed U.S.P. specifications for 9-0 sutures and were 64% stronger than 28 µm 
sutures. 48 µm PCL/8% Levo sutures, also measured via straight pull, demonstrated a 61% 
increase in tensile strength in comparison to 38 µm sutures. 
 
3.3.3. In Vivo Suture Biocompatibility 
In order to evaluate the use of electrospun, multifilament sutures as a potential alternative 
to nylon or other commercially available sutures, we assessed the tissue reaction to 10-0 
nylon, Vicryl®, PCL, PCL/8% Levo, and PCL/16% Levo sutures following implantation 
into the rat corneal stroma for 2 days. There were no gross signs of irritation, inflammation, 
or infection among any of the treated or control groups for the duration of the study. 
Histological analysis (Figure 3.3.) revealed that implantation of PCL or PCL/Levo sutures 
did not cause neovascularization, and that the tissue reaction was comparable to 
commercially available nylon sutures. Notably, a small ring of cells was observed 




3.3.4. Pharmacokinetics of Levofloxacin Delivered from Sutures 
In order to determine the duration and concentration of Levo delivery from sutures in vivo, 
we conducted a pharmacokinetic study by implanting three 2 mm lengths of 28 µm 
PCL/8% Levo and PCL/16% Levo sutures into rat corneas. Analysis of Levo concentration 
in harvested aqueous humor and corneas revealed a burst release of antibiotic following 
suture implantation and for multiple hours afterwards (Table 3.1.). The Levo release 
profiles were similar in eyes implanted with either 8% or 16% Levo sutures. However, 
eyes with PCL/16% Levo sutures contained higher concentrations of Levo in both the 
aqueous humor and cornea at almost all time points. Sutures maintained their location and 
macroscopic structure throughout the course of the study, and in both 8% and 16% Levo 
conditions, Levo was detected in the cornea and aqueous humor 14 days after implantation. 
HPLC analysis of dissolved sutures revealed Levo loading of 80 and 161 µg/m, 
respectively, for 8% and 16% Levo sutures.  
 
3.3.5. Prevention of Ophthalmic Infection 
We assessed the potential clinical utility of PCL/Levo sutures by evaluating their capacity 
to prevent infection following one or two consecutive inoculations of Staphylococcus 
aureus (S. aureus). Rat eyes were scratched, three 2 mm lengths of 10-0 nylon, Vicryl®, or 
PCL/Levo sutures were implanted into the cornea, and S. aureus was administered. Rats 
receiving implantation of nylon sutures were divided into three groups: (1) no post-
operative treatment, (2) topical administration of a single drop of 0.5% Levo immediately 
after inoculation, and (3) topical administration of 0.5% Levo three times daily beginning 
immediately after inoculation. Implantation of Vicryl® and nylon sutures without post-
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operative treatment resulted in severe infections characterized by a bacterial load 3.4 – 4.3 
times higher than that of a healthy, control cornea (Figure 3.4.A). The eyes were highly 
inflamed and red, with a whitish hue likely indicating bacterial colonization and 
proliferation surrounding the sutures themselves (Figure 3.4.B). Healthy, control corneas 
contained a small amount of endogenous bacteria, the amount of which was not 
significantly different than corneas implanted with PCL/8% Levo sutures or corneas 
implanted with nylon sutures receiving three daily drops of Levo. A single drop of Levo 
following implantation of nylon sutures significantly decreased the bacterial load in 
comparison to a nylon suture alone (p < 0.05), but was not sufficient to prevent infection 
(Figure 3.4.A). These findings are further confirmed by histological and bacterial culture 
analysis. H&E staining revealed substantial inflammation and cellular infiltration within 
the corneas of rats receiving implantation of Vicryl® or nylon sutures without post-
operative administration of Levo (Figure 3.4.C). Notably, the concentration of cells was 
greatest within the immediate vicinity of implanted sutures, providing another indication 
that the suture itself may be the nidus of infection and location of bacterial adherence. Cells 
were also concentrated around nylon sutures implanted in rat eyes receiving a single post-
operative dose of Levo. However, there was no sign of infection or inflammation in the 
corneal tissue surrounding PCL/8% Levo sutures or nylon sutures in rats receiving three 
daily doses of Levo, and the tissue resembled that of a healthy control. Culture of bacterial 
swabs on agar plates similarly confirmed the presence of infection in rats with implantation 
of Vicryl® or nylon sutures, or nylon sutures followed by a single dose of Levo 




We also evaluated the capacity of 10-0 PCL/Levo multifilament sutures to continue to 
prevent ocular infection following the immediate post-operative period. PCL/8% Levo and 
PCL/16% Levo sutures were implanted into rat corneas with administration of S. aureus 
immediately following implantation and again 5 days after implantation. Eyes containing 
nylon sutures were only inoculated once 5 days after implantation. In congruence with the 
results of the short-term infection study, eyes containing PCL/Levo sutures, at either 
concentration of Levo, did not become infected after the initial S. aureus inoculation. 
However, 7 days after implantation, 25% of eyes implanted with PCL/8% Levo sutures 
displayed a minor infection confirmed by bacterial swab and homogenization (Figure S2, 
Supporting Information). Notably, 0% of rat eyes containing 10-0 PCL/16% Levo sutures 
showed signs of infection (Figure 3.5.A). These results are significantly different (p < 
0.01) than the outcomes observed for eyes containing nylon sutures of which 100% became 
infected after a single bacterial inoculation 5 days after suture implantation. SEM images 
of sutures removed from rat corneas 7 days after implantation further confirmed these 
results (Figure 3.5.B). High magnification images revealed the presence of S. aureus on 
all nylon sutures with vast amounts of biofilm formation. S. aureus was also detected on 
PCL/8% Levo sutures collected from infected eyes, although biofilm formation was less 
apparent. S. aureus colonization was not apparent on PCL/16% Levo sutures collected 7 









Commercially available sutures are known to be associated with vision-threatening 
microbial keratitis and endophthalmitis.66,84-87,101 Suture-related complications are 
implicated in up to more than 50% of infections following penetrating keratoplasty 
procedures.84-87 Although sutures are employed in a lower percentage of cataract surgeries, 
after three years, more than 65% of sutures have been reported to become loose or broken. 
Upon removal, cultures reveal that almost 40% of such sutures demonstrate bacterial 
contamination.29 In addition, implantation of devices such as keratoprostheses in 
conjunction with sutures has demonstrated post-operative infection rates of more than 
17%.102 An antibiotic-eluting suture offers an opportunity to prevent suture-related post-
operative infections, and to reduce the risk of infection following ocular device 
implantation; however, there are currently no market offerings for drug-eluting sutures in 
ophthalmology.  
 
We designed a novel electrospinning system for manufacture of nano-structured, drug-
eluting sutures, and evaluated its potential for development of antibiotic-eluting sutures for 
ocular surgery. Degradable, multifilament sutures manufactured using this platform met or 
exceeded U.S.P. specifications for size and strength suitable for ophthalmic use. Further, 
these sutures surpassed breaking strength specifications when loaded with a wide range of 
antibiotics of different physicochemical properties. The multifilament sutures 
demonstrated biocompatibility comparable to conventional nylon sutures, and delivered 
levofloxacin at detectable levels in rat eyes for at least 14 days. Moreover, Levo-eluting, 
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multifilament sutures manufactured utilizing this platform prevented ocular infection 
against multiple bacterial challenges for a period of 1 week in vivo, and were significantly 
more effective than a single post-operative antibiotic drop at decreasing bacterial load 
within the eye.  
 
To our knowledge, this is the first manufacturing platform to produce drug-loaded sutures 
that surpass U.S.P. breaking strength specifications.12,18,20,69,76 Similar to prior reports in 
the literature, micron-sized, electrospun PCL monofilament sutures lost more than 50% of 
their strength with inclusion of Levo. In contrast, twisted, multifilament nanofiber sutures 
did not lose strength with inclusion of an equivalent amount of Levo. Both the composition 
of the sutures and the manufacturing process likely contributed to these outcomes. PCL is 
a semi-crystalline, hydrophobic, and biodegradable polymer.99 It has been shown that the 
process of electrospinning alone alters the molecular orientation of PCL to improve 
crystallinity and that PCL nanofibers increase in tensile strength with reduced diameter due 
to molecular confinement.103 This phenomenon is not observed in PCL fibers produced via 
the melt flow extrusion process used to manufacture commercially available sutures 
today.103 Further, PCL crystallinity increases along with a decrease in molecular weight.99 
We maximized fiber crystallinity, and consequently suture strength, by electrospinning 
nanofibers composed of low molecular weight PCL. Moreover, twisting of individual 
nanofibers into a multifilament suture provides additional structural reinforcement, 
resistance to breakage, and knot security.57 The flat, ribbon-shaped morphology of the 
individual nanofibers suggests that the twisting process led to stretching of nanofibers, 
which has also been shown to improve fiber crystallinity and tensile strength.104 Increased 
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twisting also resulted in a more compact nanofiber bundle, illustrated by the increased 
spray time necessary to manufacture sutures of an equivalent diameter at a higher number 
of twists. Thus, increasing the number of twists allowed for incorporation of a greater 
number of nanofibers into a single suture, thereby amplifying breaking strength and 
increasing drug loading capacity. Collectively, these factors contributed to manufacture of 
drug-loaded, multifilament PCL sutures with unprecedented strength.  
 
The highly crystalline and hydrophobic nature of PCL nanofibers manufactured through 
this process likely partitions the drug and polymer.12,103 This may explain the equivalent 
strength of multifilament PCL sutures without drug and with inclusion of 8% Levo or other 
antibiotics with disparate molecular structures. This might also lead to the burst release of 
Levo observed following implantation of drug-loaded sutures into rat eyes. Although a 
burst release of antibiotic is critical for prevention of immediate post-operative infection 
when wounds or surgical incisions are healing and most vulnerable to bacterial infiltration, 
sutures are susceptible to bacterial colonization for as long as they remain in 
vivo.29,62,81,84,85,87,101,102,105,106. Given the small diameter of sutures utilized in ophthalmic 
procedures, it is unlikely that antibiotic-coated sutures could provide sufficient drug 
delivery over this duration.14,17 However, local antibiotic delivery from drug-loaded sutures 
may preclude issues of poor patient compliance with topical eye drops, prevent suture-
related infections that lead to treatment failure and re-intervention, reduce the need for oral 
antibiotic use, decrease the risk of infection associated with implantable ocular devices, 
and serve as an alternative to the more than 12 million nylon sutures used in ocular 





Implantation of sutures or other devices into the eye increases the risk of potentially sight-
threatening ophthalmic infection. The surfaces of these devices are vulnerable to bacterial 
colonization and proliferation, and biofilm formation. We have developed a novel platform 
for manufacture of high strength, nano-structured, drug-loaded sutures capable of meeting 
U.S.P specifications for suture diameter and strength. This platform is compatible with 
several ophthalmic antibiotics of varying physicochemical properties, and can surpass 
clinical strength requirements while delivering sufficient levels of antibiotic locally. 
Multifilament nanofiber sutures manufactured utilizing this platform demonstrated 
biocompatibility and prevention of ophthalmic infection following multiple inoculations 
of S. aureus over a period of one week. This platform for suture manufacture is highly 























Figure 3.1. Manufacture of drug-eluting, multifilament sutures.  
(A) Schematic of suture manufacturing system: high voltage is applied to a polymer or 
polymer/drug solution pumped at a controlled rate perpendicular to two grounded 
collectors. One collector is motorized, allowing for twisting of hundreds of parallel 
nanofibers into a single, multifilament suture. (B) SEM images of a conventional 10-0 







Figure 3.2. Breaking strength of PCL sutures in reference to U.S.P. specifications.  
(A) Comparison of breaking strength of 28 µm PCL/8% Levo monofilaments vs 28 µm 
PCL/8% Levo multifilaments at varying levels of twisting. (B) Breaking strength of 28 µm 
multifilament sutures at 1,575 twists composed of PCL and 8% of different ophthalmic 
antibiotics. (C) Breaking strength of 28 µm PCL/Levo multifilament sutures at 1,575 twists 
at a range of Levo concentrations. (D) Breaking strength of PCL/8% Levo multifilament 
sutures at 1,575 twists at a range of diameters suitable for ophthalmic surgery. Note that 
all sutures were measured by straight pull. Difference in number of * indicates statistical 












Figure 3.3. Histological analysis of suture biocompatibility.  
Representative images of H&E-stained tissue surrounding Vicryl®, Nylon, PCL, PCL/8% 
Levo, and PCL/16% Levo sutures implanted into rat corneas for 2 days. Control indicates 










Table 3.1. Levofloxacin concentration in rat corneal tissue and aqueous humor.  
Concentration of levofloxacin within rat cornea and aqueous humor following implantation 













Figure 3.4. Evaluation of ophthalmic infection 2 days after inoculation of S. aureus.  
(A) Concentration of bacteria in healthy control rat corneas or inoculated corneas 
containing either Vicryl®, Nylon, or PCL/8% Levo sutures. Nylon sutures were evaluated 
alone, with treatment of a single post-operative topical drop of 0.5% Levo, or with 
treatment of 3 daily drops of 0.5% Levo. Representative images of (B) healthy control and 
experimental eyes 2 days after bacterial inoculation, and (C) H&E stained tissue 









Figure 3.5. Evaluation of ophthalmic infection following consecutive S. aureus 
inoculations over the period of 1 week.  
(A) Kaplan-Meier curve indicating prevention of ophthalmic infection following 
inoculation of on day 0 and day 5 of Sprague Dawley rat corneas implanted with either 
PCL/8% Levo or PCL/16% Levo sutures. Note that all sutures were implanted on day 0 
and that corneas containing nylon sutures were only inoculated once, on day 5. * indicates 
statistical significance at p < 0.01. (B) High magnification SEM images of nylon (top), 
PCL/8% Levo (middle), or PCL/16% Levo (bottom) sutures removed from rat corneas on 






4. Rapamycin-eluting, nanofiber-coated sutures for inhibition of 




Vascular anastomoses, or surgical connections between arteries and/or veins, are one of 
the most common surgical procedures involved in millions of vascular bypass, vascular 
access, solid organ transplant, and reconstruction procedures each year.108-112 In each 
case, damage to the vessel walls during the surgical procedure, most often using sutures, 
leads to deposition of platelets which release inflammatory chemokines and platelet-
derived growth factor.113-115 This cascade signals the inward migration and proliferation 
of smooth muscle cells, or neointimal hyperplasia, resulting in thickening of the vessel 
wall.114,115 The resulting stenosis, or narrowing of the vessel lumen, is the major cause of 
arterial, venous, arteriovenous, and prosthetic graft failure.36-40,116,117 Approximately 30% 
of all arterial bypass grafts and 50% of venous grafts fail due to neointimal 
hyperplasia.115 Permanent vascular access is critical for patients with chronic kidney 
disease or end-stage renal undergoing hemodialysis; however, failure rates are reported as 
high as 50%, and vascular access complications are responsible for 20% of patient 
hospitalizations.111,117,118 There is a significant and unmet clinical need for anastomotic 
closure with reduced complications, particularly with regard to neointimal hyperplasia.   
 
Several less-invasive closure technologies have been developed over the past few 
decades, including clips, adhesives, lasers, sleeves, rings, stents, and other devices; 
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however, each has its own limitations for use and/or complications, such as toxicity, 
leakage, occlusion, loss of strength, or the need to implant multiple devices.113,119-126 
Thus, non-absorbable nylon sutures remain the gold standard for anastomotic closure due 
to their convenience, reliability, flexibility, and capacity to provide strength at the 
anastomotic site for an extended period of time.113  
 
Local delivery of anti-proliferative drugs such as rapamycin (Rap) or paclitaxel may 
provide an alternative to changes in surgical procedure. The Cypher® rapamycin-eluting 
coronary stent first demonstrated the clinical benefit of local anti-proliferative delivery by 
preventing hyperplasia, and unlike oral delivery of rapamycin, demonstrated superiority 
to bare metal coronary stents for an extended period of time at a lower drug dosage.127-132 
Over the past decade, interest in the development of drug-eluting sutures has grown with 
the objective of providing local drug delivery at the surgical site to prevent complications 
and/or enhance wound healing. Literature reports have demonstrated delivery of a wide 
range of prophylactic and therapeutic moieties, including antibiotics, growth factors, 
anesthesia, and even tacrolimus for prevention of neointimal hyperplasia.7,11-22,75 
However, clinical translation of such technologies has been curtailed due to an inability 
to meet United States Pharmacopeia (U.S.P.) specifications for suture size and strength, 
provide sufficient and sustained drug delivery, and/or scale to commercial 
viability.12,14,17,75 Thus, to date, the only market offerings are triclosan-coated sutures 
indicated for anti-infection applications in general surgery, and there are no drug-eluting 




In order to provide for successful anastomotic closure while also preventing neointimal 
hyperplasia, a suture must: (1) surpass U.S.P. specifications for suture strength, and 
maintain strength at the anastomotic site for an extended period of time; (2) meet size 
requirements for sutures used in vascular surgery (U.S.P. sizes 9-0 – 7-0; 30-69 µm in 
diameter); (3) provide sufficient delivery of an appropriate drug; (4) have potential to 
scale its manufacturing.133 Here, we investigate the use of a novel electrospinning system 
to produce highly tunable, drug-eluting, nanofibrous coatings for sutures. Electrospinning 
is an adaptable, well-understood process in which high voltage can be applied to a 
polymer or polymer/drug solution to draw out solid nanofibers and microfibers.6 
Specifically, we describe the manufacture of an 8-0-sized, non-absorbable suture with a 
nylon core and nanofiber coating composed of rapamycin, poly(L-lactide) (PLLA), and 
polyethylene glycol (PEG). Originally used as an anti-fungal agent, rapamycin has been 
shown to be a potent anti-proliferative and anti-inflammatory drug which inhibits the 
mammalian target of rapamycin (mTOR) pathway.134 PLLA and PEG are generally 
regarded as safe polymers (GRAS) that have been widely utilized in drug delivery 
applications, and are already incorporated in medical devices approved by the United 
Stated Food and Drug Administration.66 We investigate suture morphology, breaking 
strength, drug release, and capacity for anastomotic closure and inhibition of neointimal 







4.2. Materials and Methods 
 
4.2.1. Suture Fabrication 
Polymer solutions were made via dissolution of PLLA (221 kDa; Corbion, Amsterdam, 
Netherlands), PEG (35 kDa; Sigma Aldrich, St. Louis, MO), and rapamycin (LC 
Laboratories, Woburn, MA) in hexafluoroisopropanol (Sigma-Aldrich) by shaking 
overnight at room temperature. Polymer to solvent concentration was maintained at 
10.8% and PEG to PLLA concentration was maintained at 3.9% for all formulations. 
Rapamycin concentration was 20%, 40%, or 80% in regard to PLLA for the 20% 
Rap/PLLA/PEG, 40% Rap/PLLA/PEG, and 80% Rap/PLLA/PEG formulations, 
respectively. Prior to electrospinning, the non-needled end of a 10-0 nylon suture 
(Ethicon, Somerville, NJ or AROSurgical Instruments, Newport, CA) was placed into the 
rotational collector. The needled end was driven through the hole in the opposing 
collector and allowed to hang loosely. Rap/PLLA/PEG solutions were then pumped 
through a 20 G blunt-tip needle at 1 mL/h with an applied voltage of 15 kV at a distance 
of 17 cm from the parallel, grounded collectors. The collector containing the non-needled 
end of the suture was then rotated clockwise for five minutes at 150 rpm and counter-
clockwise for 30 s at an identical speed. The suture was then removed from the collectors 







4.2.2. Suture Characterization 
 
4.2.2.1. Suture Size  
Suture diameter was determined via light microscopy (Eclipse TS100, Nikon 
Instruments, Melville, NY) and calibrated imaging software (Spot 5.2 Basic, Spot 
Imaging, Sterling Heights, MI). Each suture was measured at four different locations at 
least 2 cm apart, and used in further experimentation only if the average diameter was 
between 46 and 49 µm, qualifying as an 8-0 suture.  
  
4.2.2.2. Suture Morphology 
Nylon and nanofiber-coated suture morphology were observed via scanning electron 
microscopy (SEM) at 1 kV using a LEO Field Emission SEM (Zeiss, Oberkochen, 
Germany). Prior to SEM, sutures were sputter coated with 10 nm of Au/Pd (Desk II, 
Denton Vacuum, Moorestown, NJ). 
 
4.2.2.3. In Vitro Drug Release 
20, 40, and 80% Rap/PLLA/PEG formulations were electrospun and twisted into 20 µm 
diameter fiber bundles (n = 4 for each condition). Fibers were cut to 15 mm in length and 
submerged in 200 µL of 1x Dulbecco’s Phosphate-Buffered Saline (PBS, Fisher 
Scientific, Waltham, MA) containing 0.5% (w/vol) Tween-20 (Fisher Scientific). 
Samples were placed on an orbital shaker at 37 ⁰C, with the release medium collected and 
replenished with fresh media at 4 h, and at 1, 3, 5, 8, 11, and 14 days. Rapamycin 
concentration within the release media was measured via high performance liquid 
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chromatography (HPLC; Waters Corporation, Milford, MA) analysis. Samples were 
injected into a SymmetryTM 300 C18 5 µm column (Waters Corporation) with a mobile 
phase of water and methanol (30:70 v/v, Fisher Scientific) at a flow rate 0.8 mL/min for 
30 min. Rapamycin elution was detected at a wavelength of 278 nm. 
 
4.2.2.4. Suture Breaking Strength  
Nylon sutures were coated with 20 and 40% Rap/PLLA/PEG nanofibers (n = 4 for each 
condition) and tied into a surgeon’s knot, clamped vertically, and pulled until breaking at 
a rate of 16 mm/min using an 5966 Dual Column Tabletop Testing System (Instron, 
Norwood, MA). 
 
4.2.3. Animal Studies 
All animals were cared for and experiments conducted in accordance with protocols 
approved by the Animal Care and Use Committee of the Johns Hopkins University, and 
in compliance with the National Institutes of Health guidelines for the Care and Use of 
Laboratory Animals.  
 
Briefly, female Lewis rats (Hilltop Lab Animals, Scottdale, PA and Harlan Laboratories, 
Frederick, MD) were anesthetized via intraperitoneal injection of ketamine (50mg/kg) 
and xylazine (5mg/kg), and kept under anesthesia with 2% isoflurane in oxygen during 
the procedure. A portion of the infrarenal abdominal aorta was exposed and cross-
clamped, after which three-quarters of the circumference of the aorta was sectioned. The 
sectioned aorta was then repaired via interrupted suturing using 8-0 nylon (Ethicon), 20% 
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Rap/PLLA/PEG/Nylon, or 40% Rap/PLLA/PEG/Nylon sutures (n = 6 for each 
condition). The patency of the anastomosis and ensuing hemostasis were confirmed prior 
to closure of the abdomen. Animals were monitored daily for 14 days for signs of 
infection or irritation, after which the abdominal aorta was harvested and fixed in 
formalin (Sigma Aldrich) for 24 h. 
 
4.2.3.1. Evaluation of neointimal hyperplasia 
Harvested tissue was embedded in paraffin, cross-sectioned, and stained with 
hematoxylin and eosin (H&E). Only sections containing sutures, indicating the 
anastomotic region, were utilized for evaluation of neointimal hyperplasia. Two 
measurements of neointimal hyperplasia thickness were taken for each section and then 
averaged. The individual sections at the anastomotic site were then averaged together for 
each replicate for each suture condition.    
 
4.2.4. Statistical Analysis 
Suture breaking strength, suture drug release, and neointimal hyperplasia are presented as 
mean ± standard error. Statistical significance for suture breaking strength was 
determined via Student’s t-test. Statistical significance for neointimal hyperplasia was 









4.3.1. Fabrication and Characterization of Nanofiber-coated Sutures 
We hypothesized that coating a non-absorbable, nylon suture with absorbable, 
rapamycin-loaded nanofibers would simultaneously provide for sufficient drug release 
and sustained strength at the anastomotic site in order to provide for appropriate wound 
healing with reduced post-operative complications.  
 
In order to coat a standard nylon suture in a uniform, reproducible, and highly tunable 
manner, we adapted the novel manufacturing system described in Chapter 3 consisting of 
a syringe pump with a polymer/drug solution perpendicular to a pair of grounded 
collectors, one of which is capable of rotation. The non-needled end of the nylon suture 
was attached to the collector capable of rotation, and the needled end of the suture was 
placed through the opposing collector (Figure 4.1.A). 20, 40, and 80% Rap/PLLA/PEG 
solutions were electrospun into nanofibers which deposited between the two parallel, 
grounded collectors, and were then twisted around the nylon suture by rotating the 
collector attached to the non-needled end of the suture.  
 
Several electrospinning parameters, such as flow rate, applied voltage, and distance to 
collectors were optimized in order to manufacture nanofibers composed of rapamycin, 
PLLA, and PEG. Figure 4.1.B depicts a 10-0 nylon suture before (bottom) and after (top) 
coating with rapamycin-loaded nanofibers. Notably, coating thickness is reproducibly 
tunable and can be adjusted in a facile manner by modifying spray time. SEM images 
58 
 
displayed manufacture of non-porous, defect-free nanofibers wound tightly around the 
nylon thread core to form a nanofiber-coated suture. Thin and short polymeric fibers were 
also dispersed around the outside of the coating. Figure 4.1.C depicts both the nylon 
suture and coated nylon suture at a lower magnification, demonstrating the uniformity of 
the coating along the length of the suture.  
 
The major challenge in the translation of drug-eluting sutures has been the inability to 
simultaneously surpass U.S.P. requirements for suture breaking strength while also 
providing sufficient and sustained drug delivery. Thus, we next examined the drug 
release profiles and breaking strength of Rap/PLLA/PEG/Nylon sutures.  
 
4.3.2. In Vitro Release of Rapamycin from Nanofiber-coated Sutures 
Previous studies in the literature have suggested that the addition of a small percentage of 
a hydrophilic moiety such as PEG can improve the release kinetics of a hydrophobic drug 
from a similarly hydrophobic polymeric matrix.75 20, 40, and 80% Rap/PLLA/PEG 
nanofibers each demonstrated continued rapamycin release in vitro for at least 14 days 
(Figure 4.2.). However, the release profiles of each nanofiber formulation varied 
drastically. The 20 and 40% formulations both demonstrated sustained release of 
rapamycin in vitro. However, as the concentration of drug within the formulation 
increased, a more pronounced burst effect was observed. A burst release profile was 
observed for both the 40 and 80% suture formulations with the majority of the rapamycin 




4.3.3. Nanofiber-coated Suture Breaking Strength 
Based on the results of the in vitro drug release study, 20 and 40% Rap/PLLA/PEG 
coating formulations were chosen as lead candidates due to their capacity for sustained 
release. We next evaluated the breaking strength of 10-0 nylon sutures coated with either 
20 or 40% Rap/PLLA/PEG nanofibers. According to the U.S.P., synthetic sutures 
resistant to the action of living mammalian tissue with a coating that adds significantly to 
suture diameter, but not to suture strength, are classified as Class II, non-absorbable 
surgical sutures.133 The coating process used in this study increased the size of a standard 
10-0 nylon suture to between 46 and 49 um, thus decreasing the U.S.P. size to 8-0.133 The 
minimum average knot-pull tensile strength requirement for an 8-0, non-absorbable, 
Class II suture is 0.39 N.133 As shown in Figure 4.3., both 20 and 40% 
Rap/PLLA/PEG/Nylon sutures surpassed U.S.P. specifications for suture breaking 
strength by more than 30%. Moreover, because suture strength is derived from the nylon 
core, doubling the concentration of rapamycin within the coating formulation did not 
significantly affect suture strength 
 
4.3.4. Effect of Rapamycin Nanofiber Coating on Post-operative Neointimal Hyperplasia 
Finally, we evaluated the potential clinical utility of rapamycin nanofiber-coated nylon 
sutures by determining their capacity to maintain an anastomotic site and decrease local 
neointimal hyperplasia. Following sectioning of the rat abdominal aorta, the vessel was 
anastomosed via interrupted suturing using 8-0 nylon, 20% Rap/PLLA/PEG/Nylon, or 
40% Rap/PLLA/PEG/Nylon sutures. No suture-related complications were observed 
during any of the procedures. The nanofiber-coated nylon sutures were able to pass 
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through the tissue several times and suture the vessel appropriately without any peeling 
or loss of the coating. Further, vessel patency and hemostasis were confirmed 
immediately post-operatively in all cases. No anti-platelet or anti-coagulation therapy, or 
any other kind of therapy was provided in the 14 day post-operative period, and there was 
no operative or suture-related infection or mortality at any time under any condition.  
 
After 14 days, rat abdominal aortas were harvested and evaluated grossly and via 
histology. In all cases, the sutures remained in place, and there was no leakage observed 
at the anastomotic site. H&E staining of tissue sections at the anastomosis confirmed the 
presence of neointimal hyperplasia within the inner lumen of vessels sutured using nylon 
(Figure 4.4.A), 20% Rap/PLLA/PEG/Nylon (Figure 4.4.B), and 40% 
Rap/PLLA/PEG/Nylon (Figure 4.4.C) sutures, indicated by a highly inflamed, pink-
colored tissue region often adjacent to the sutures themselves. However, there was a 
significant reduction in neointimal hyperplasia thickness in tissues anastomosed using 
rapamycin-eluting sutures (Figure 4.4.D). Vessels anastomosed using either of the drug-
eluting sutures displayed significantly lower (p < 0.01) neointimal hyperplasia thickness 
in comparison to vessels sutured using the standard nylon suture. Further, 40% 
Rap/PLLA/PEG/Nylon sutures significantly decreased (p < 0.01) neointimal hyperplasia 
in comparison to 20% Rap/PLLA/PEG/Nylon sutures, and reduced neointimal 








The local vascular smooth muscle cell population is multiplied up to five times in the 14 
days following vascular anastomoses.114 This post-operative inflammatory response 
contributes to 90% of the ultimate neointimal hyperplasia, and the resulting stenosis can 
have devastating consequences, including re-operation, graft/transplant failure, and 
death.111,114,116,118 Thus, it is critical to modulate the local, post-operative biological 
response in order to improve the outcomes of arterial, venous, arteriovenous, and 
prosthetic graft procedures.  
 
We developed a new method to endow conventional sutures with drug delivery 
functionality via a nanofiber coating, and evaluated its potential for use in vascular 
anastomosis procedures. Rapamycin-eluting, nanofiber coatings demonstrated uniformity 
along the length of the suture and remained intact while suturing in vivo. Further, this 
coating method allowed for facile tuning of nanofiber coating thickness and rapamycin 
release profile. Importantly, Rap/PLLA/PEG/Nylon sutures met or exceeded U.S.P. 
specifications for 8-0 suture diameter and strength, and reduced neointimal hyperplasia in 
comparison to a standard 8-0 nylon suture following anastomosis of the abdominal aorta 
in rats.  
 
Rapamycin was chosen for this study due its extensive use, well-known mechanism of 
action, and demonstrated ability to reduce neointimal hyperplasia and stenosis in both 
experimental models and in the clinic.114,119,122,128,129 However, there has been a concern 
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that while the anti-proliferative activity of rapamycin may inhibit neointimal hyperplasia, 
it may also inhibit appropriate endothelialization and healing at the anastomotic site.15 In 
this study, both rapamycin-eluting suture conditions demonstrated a significant reduction 
in neointimal hyperplasia while also maintaining the vascular anastomosis through the 
duration of the study. Thus, it appears that the capacity of the nanofiber coatings to 
deliver low levels of drug in a sustained manner may provide sufficient modulation of the 
post-operative inflammatory response while also allowing for appropriate vessel healing. 
Further, major advantages of this platform are the versatility of electrospinning to 
incorporate almost any polymer and/or drug, and that the nanofiber coating is not 
required to contribute to suture strength.65 Thus, almost any polymer/drug formulation 
can be implemented to achieve the appropriate release of the active agent in a manner 
that both significantly reduces neointimal hyperplasia and stenosis while promoting long-
term vascular health. The use of this highly versatile and tunable coating platform as a 
research tool may help to further elucidate the types of drugs and release profiles that are 
conducive to realizing both objectives. 
 
Another advantage of this coating method is its potential to incorporate multiple types of 
fibers into a single, tightly wound coating. For example, a coating composed of both 
short- and long-term degradation fibers could be used to provide early- and extended-
term drug release to prevent both immediate- and late-stage complications. Our studies 
demonstrated that an initial burst release of rapamycin may improve outcomes; however, 
extended release of rapamycin will useful in conjunction with non-absorbable sutures 
which are a source of inflammation as long as they are present at the anastomotic site.113-
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115 Additionally, the nanofiber coating could be designed to release an anti-proliferative 
drug to reduce neointimal hyperplasia and an antibiotic to prevent infection, which is 
another leading cause of prosthetic graft failure.111,117  
 
Although the nanofiber-coated nylon sutures described in this study surpassed U.S.P. 
requirements for suture strength and maintained the anastomotic site for at least 14 days, 
it is important to note that the U.S.P. only specifies a minimum average suture breaking 
strength. Prior to clinical studies, it will be important to evaluate the durability of 
nanofiber-coated sutures in larger animal models and in different types of anastomoses 
for a longer duration to ensure that they maintain the anastomosis. If they are successful, 
nanofiber-coated sutures may have significant potential for use in vascular anastomosis 
procedures due to their capacity to reduce neointimal hyperplasia without changing the 




This study demonstrated the manufacture of a nanofiber-coated, nylon suture capable of 
meeting U.S.P. specifications for suture size and strength for vascular surgery, providing 
sustained release of rapamycin, maintaining the anastomotic site, and reducing post-
operative neointimal hyperplasia in a rat model of vascular anastomosis. The coating is 
composed of GRAS materials, and did not peel or disintegrate during the surgical 
procedure. This platform has the potential to reduce post-operative complications and 
improve the clinical outcomes following vascular bypass and vascular access surgeries, 
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which present a significant economic and health burden, without modifying the current 



























Figure 4.1. Manufacturing schematic and SEM images of nanofiber-coated sutures.  
(A) Schematic of suture coating system: high voltage is applied to the nozzle of a syringe 
containing a volatile polymer/drug solution which is pumped at a controlled rate. 
Electrospun fibers are deposited between two parallel grounded collectors surrounding a 
standard suture attached to one collector and driven through the opposing collector. 
Following fiber deposition, one collector is mechanically rotated to twist deposited fibers 
into a uniform coating around the suture. (B) High magnification SEM image of a 10-0 
nylon suture (bottom) and a 10-0 nylon suture coated with Rap/PLLA/PEG nanofibers 
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(top). (C) Low magnification SEM image of a highly uniform nanofiber-coated 10-0 
































Figure 4.2. Cumulative in vitro release of rapamycin.  
 In vitro release profiles of rapamycin from PLLA/PEG nanofibers containing different 

























Figure 4.3. Breaking strength of nanofiber-coated nylon sutures in reference to 
U.S.P. specifications. 
 Comparison of knot-pull breaking strength of 8-0-sized Rap/PLLA/PEG/Nylon sutures 
containing 20% or 40% rapamycin within the coating formulation. Sutures are classified 
















Figure 4.4. Evaluation of neointimal hyperplasia following vascular anastomosis. 
Representative images of H&E-stained tissue sections of rat abdominal aorta 14 days 
after anastomosis procedure using (A) nylon suture (8-0), (B) 20% 
Rap/PLLA/PEG/Nylon suture (8-0), and (C) 40% Rap/PLLA/PEG/Nylon suture (8-0). 
Black arrows indicate regions of neointimal hyperplasia. (D) Quantification of neointimal 





5. Reduction of intraocular pressure in rabbits via a nano-structured 




Glaucoma is a leading cause of irreversible vision loss and a growing worldwide problem. 
Over 60 million people were affected by this vision threatening disease in 2010, and this 
number is predicted to almost double by 2040.42,43 Approximately 8 million people were 
bilaterally blind due to glaucoma in 2010 and it is predicted that this number will rise to 
more than 12 million in 2020.42 Intraocular pressure (IOP) reduction prevents the 
development of glaucoma and vision loss from glaucoma.44,45 Clinically, physicians use 
medications, laser procedures, and/or incisional surgeries to lower IOP. Topical 
medications are the first-line therapy as they can effectively reduce IOP while avoiding the 
risks associated with more invasive procedures and surgeries. However, topical 
medications do not always lower IOP sufficiently to halt disease progression, are associated 
with poor patient adherence, and can cause symptomatic eye surface irritation and 
redness.135  
 
The greater risk associated with surgical approaches to IOP reduction is partly attributed 
to a lack of standardization correlated with post-operative complications.46,50 The most 
frequently performed IOP-lowering surgeries create a vent to release pressure from the 
eye.136 The specific IOP at which these vents function is often determined by ad hoc 
interventions performed by the surgeon that are at risk for variability from surgeon to 
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surgeon and by individual surgeons from procedure to procedure. The trabeculectomy is 
the most commonly performed incisional glaucoma surgery, and was performed in 23,877 
Medicare beneficiaries in 2012.137 Fluid flow through the venting region of a 
trabeculectomy is regulated by the tension created by sutures that secure a flap of scleral 
tissue. This process leads to inconsistent outcomes, as sutures often need to be cut in the 
post-operative period due to inadequate IOP reduction, and the frequency of post-operative 
hypotony can exceed 10%.47,51 Hypotony – a term that describes IOPs that are too low – 
most commonly occurs at IOPs lower than 5 mmHg and can be associated with blurry 
vision, macular folds, choroidal detachments, and anterior chamber shallowing.138  
 
Aqueous tube shunts that drain to subconjunctival reservoirs offer an alternate surgical 
approach to IOP reduction that has increased in popularity over the past decade. Tube shunt 
insertion in Medicare beneficiaries increased from 6,307 in 2002 to 12,021 in 2012.137 
However, these devices are still susceptible to post-operative complications, and surgeons 
have had to devise a number of strategies to minimize post-operative hypotony. The 
Baerveldt® glaucoma drainage implant (GDI) requires formation of a fibrotic capsule 
around the implant in order to prevent hypotony, but this process does not occur until 
several weeks following surgery. Thus, the tube must be occluded or tied off for a period 
of 4-6 weeks in the post-operative period prior to capsule formation.139 This strategy either 
allows for no IOP reduction in the immediate post-operative period or requires the surgeon 
to create venting incisions in the tube that can lead to inconsistent outcomes.140,141 The 
Ahmed GDI contains a valve that is designed to vent above IOPs of 7 mmHg; however, 
pre-implantation testing of Ahmed valves revealed that 16% of valves did not meet this 
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specification (either vented bellow 7 mmHg or above 15 mmHg).142 These cases highlight 
the need for a more standardized, safer approach to glaucoma surgery. 
 
More recently developed GDIs standardize venting IOP and reduce the risk of post-
operative hypotony by utilizing dimensions modeled by the Hagen-Poiseuille equation 
(HPE):  
      𝛥𝑃 = 8µ𝐿𝑄
𝜋𝑟4
      (1)  
The HPE calculates resistance of an incompressible, Newtonian fluid in laminar flow 
through a cylindrical tube.143 When applied to IOP reduction in the eye, the venting 
resistance (ΔP) to fluid outflow is inversely proportional to radius raised to the fourth 
power (r4) and directly proportional to tube length (L), aqueous humor volumetric flow rate 
(Q), and aqueous humor viscosity (µ). The XEN45 microfistula implant has an internal 
diameter of 45 µm and a length of 6 mm.143-145 Fluid flowing through this device at a 
physiological flow rate of 180 µl/h creates a pressure differential of 6.28 mmHg, 
theoretically avoiding IOPs associated with the complications of hypotony.143 The 
dimensions of the InnFocus Microshunt® (inner luminal diameter of 70 µm, length of 8.5 
mm) are similarly designed to maintain an IOP greater than 5 mmHg.146,147  
 
In addition to device design and dimension, material composition can also affect GDI 
effectiveness.148 The ideal material must provide flexibility to conform to the contours of 
the eye, strength to remain patent in vivo, and be non-immunogenic.143,147,149 
Electrospinning is a promising platform for the development of shunts for glaucoma 
surgery, as it allows for incorporation of almost any polymer and prophylactic or 
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therapeutic moiety into nano or microfibers which can be configured into devices of 
various dimensions and conformations.6,65 To date, this approach has been used widely in 
tissue engineering, and more recently, in the manufacture of medical devices, such as 
sutures.150 Here, we describe an electrospinning platform that can create small lumen 
cylindrical shunts and explore whether these devices are suitable for use as GDIs.   
 
5.2. Materials and Methods 
 
5.2.1. Simulation of Flow through Shunt 
Modeling of pressure differential through the shunt was accomplished through use of 
MATLAB® (Mathworks, Natick, MA) and according to the HPE equation by varying flow 
rate, shunt diameter, and shunt length. The viscosity (0.72 cP) and average flow rate (150 
µL/h) of human aqueous humor at physiological conditions were input for the values of µ 
and Q, respectively.143   
 
5.2.2. Electrospun Shunt Manufacture 
PET shunts were manufactured through electrospinning by utilizing a grounded collector 
consisting of a drill chuck (McMaster-Carr, Elmhurst, IL) and parallel collector stand 
positioned perpendicular to the polymer jet. Stainless steel wire with a diameter of 50 µm 
(McMaster-Carr) was inserted through a 25 G, 3.81 cm long, blunt tip needle (Nordson 
EFD, Westlake, OH) which was then placed into the head of the drill chuck. PET (gift from 
Nanofiber Solutions, Columbus, OH) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol 
(Sigma Aldrich, St. Louis, MO) at 10 wt% by stirring at 45 ⁰C for 24 h. The polymer 
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solution was then electrospun onto the wire rotating clockwise at 175 rpm by applying 15 
kv of voltage from a power supply (Glassman High Voltage, High Bridge, NJ) to a 20 G 
blunt tip needle (Nordson EFD) with the polymer solution flowing at a controlled rate of 
1.5 mL/h using a programmable syringe pump (New Era Pump Systems, Farmingdale, NY). 
The shunt was then heated in an oven (Sheldon Manufacturing, Cornelius, OR) for 24 h at 
100 ⁰C prior to cooling to RT.  
 
5.2.3. Shunt Characterization 
Outer shunt diameter was measured via optical microscopy using an Eclipse TS100 (Nikon 
Instruments, Melville, NY). Inner lumen diameter and shunt morphology were examined 
via scanning electron microscopy (SEM) at 1 kv with a LEO Field Emission SEM (Zeiss, 
Oberkochen, Germany) following desiccation for at least 24 h and sputter coating with 10 
nm of Au/Pd. Imaging was conducted prior to removal of the template wire, after removal 
of the wire, and following in vitro fluid flow studies.  
 
5.2.4. Evaluation of In Vitro Fluid Flow through Shunt 
PET Shunts were cut to 5, 6, or 7 mm in length (n = 3 for each length), after which the 
template wire was removed. The shunt was then connected in circuit to a syringe pump and 
manometer (NETECH, Farmingdale, NY) via the 25 G needle. All flow studies were 
conducted at RT. 1x Dulbecco’s Phosphate Buffered Saline (PBS, ATCC, Manassas, VA) 
was pumped through the shunt at 50, 100, and 200 µL/h. Prior to flow studies, PBS was 
pumped through a 25 G needle at the specified flow rate and the resulting pressure 
measurement was subtracted from the pressure observed with attachment of the PET shunt. 
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Pressure measurements were recorded at least 30 min after a change in flow rate and only 
if the pressure remained constant for more than 5 min. Long-term flow studies (n = 3) were 
conducted by flowing PBS through a 6 mm shunt at 150 µL/h for 7 days. Theoretical 
pressure estimates were obtained from the HPE with tube diameter of 50 µm and 25 ⁰C 
PBS viscosity of 0.9 cP.151 
 
5.2.5. In Vivo Performance and IOP Measurement 
All animals involved in these studies were cared for in accordance with protocols approved 
by the Johns Hopkins University Animal Care and Use Committee. Protocols are also in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research. New Zealand White rabbits (Robinson Services, Mocksville, NC) were sedated 
by subcutaneous injection of Ketamine:Xylazine (75:5 mg/kg, Sigma Aldrich). A drop of 
0.5% proparacaine hydrochloride ophthalmic solution (Bausch & Lomb, Tampa, FL) 
followed by a drop of 5% betadine solution (Alcon, Fort Worth, TX) was administered to 
the operative eye. After placement of an 8-0 silk, stay suture (Ethicon, Somerville, NJ) in 
the superotemporal limbus, a two-clock hour, fornix-based peritomy was created 
superotemporally, and the conjunctiva was dissected posteriorly. A 25 G needle (Fisher 
Scientific, Waltham, MA) was used to create a 2 mm long scleral tunnel prior to entering 
the anterior chamber. The shunt was gently guided through this tunnel. Once the shunt was 
in position, the template wire was removed and a 10-0 nylon cross-stitch (Ethicon) was 
placed at the site of tube entry to prevent fluid leakage around the tube. Balanced saline 
solution (BSS, Alcon) was irrigated in the anterior chamber using a 30 G needle (Fisher 
Scientific) to validate shunt patency. The conjunctiva was approximated to the limbus 
76 
 
using two 10-0 nylon sutures and, again, BSS was irrigated into the anterior chamber to 
ensure that a water-tight bleb had formed. The stay suture was then removed and topical 
antibiotic ointment was administered to the eye. In this manner, 3 open lumen and 3 closed 
lumen (containing the template wire) PET shunts were implanted. All shunts were 6 mm 
in length. Rabbits were monitored daily for signs of infection, inflammation, or irritation, 
and were monitored periodically through the duration of the experiment. IOP was measured 
and calibrated as previously reported.152 Briefly, IOP was measured at 1, 4, 7, 11, 14, 21, 
and 27 days using a TonoVet (iCare, Vantaa, Finland) rebound tonometer in awake, 
restrained rabbits without topical anesthesia.  
 
5.2.6. Assessment of In Vivo Biocompatibility 
Following IOP measurement 27 days after implantation, rabbits were euthanized and eyes 
enucleated, fixed in formalin (Sigma Aldrich), embedded in paraffin, cross-sectioned, and 
stained with hematoxylin and eosin for histological evaluation. 
 
5.2.7. Statistical Analysis 
Results are presented as mean ± SE. IOP data were analyzed using a Student’s t-test, and 










5.3.1. Simulated Pressure Change 
Under physiological conditions, aqueous humor is an incompressible, Newtonian fluid.143 
Thus, by utilizing the HPE and physiological values of aqueous humor viscosity and flow 
rate, it is possible to determine the dimensions of a non-valved, cylindrical shunt capable 
of providing IOP reduction while also providing sufficient resistance to flow to prevent 
hypotony (Figure 5.1.A). Through variation of shunt diameter with flow rate held constant 
at 150 µL/h, simulations revealed that a cylindrical shunt with inner diameter ≥ 75 µm will 
lead to hypotony at any physiologically relevant shunt length (Figure 5.1.B). However, a 
shunt with a 50 µm inner diameter and greater than 4 mm in length may provide sufficient 
resistance to flow to maintain IOP above 5 mmHg. In order to achieve significant IOP 
reduction while simultaneously avoiding hypotony, 5-6 mm long shunts may be ideal. 
Through variation of shunt length with inner diameter held constant at 50 µm, our 
simulation confirmed that a 6 mm long shunt is likely to avoid IOPs associated with 
hypotony, even if aqueous humor flow rate were to fall below its physiological average of 
150 µL/h (Figure 5.1.C).    
 
5.3.2. Shunt Fabrication and Characterization 
Based on the modeling of aqueous humor flow through a cylindrical shunt at physiological 
conditions, non-absorbable, nano-structured shunts were manufactured using the 
electrospinning setup depicted in Figure 5.2.A with the cross-sectional dimensions shown 
in Figure 5.2.B. 15 kV of voltage was applied to a 10 wt% solution of PET in HFIP flowing 
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at 1.5 mL/h perpendicular to a rotating, grounded, stainless steel wire. This provided for a 
dense and uniform coating of PET nanofibers onto the template wire with low wall porosity 
following heat treatment (Figure 5.3.A). In order to achieve high strength and maintain 
lumen integrity in vivo, shunts were manufactured with a wall thickness of 354 ± 15 µm, 
and composed of nanofibers, which demonstrate a higher tensile modulus than larger 
diameter electrospun fibers.103 5, 6, and 7 mm long shunts were manufactured with an 
internal lumen diameter of 50 µm formed via removal of a 50 µm template wire. Prior to 
in vitro flow studies, the shunt was cut to the appropriate size, and the template wire 
(Figure 5.3.B) was removed from the inner lumen (Figure 5.3.C).  
 
5.3.3. In Vitro Performance and Flow through Shunt 
Electrospun shunts were evaluated in vitro to determine if they are leak-proof, durable, and 
provide the resistance to flow predicted by the HPE. PBS was pumped through 6 mm long 
PET shunts at a flow rate of 150 µL/h for a period of one week to evaluate shunt integrity 
and durability. As shown in Figure 5.3.D, the lumen of the shunt remained patent and 
maintained its size after one week of continuous flow. The inner surface of the shunt was 
composed of aligned nanofibers showing no degradation or breaking. Moreover, leakage 
of PBS through the shunt wall was not observed through the duration of the study. 
 
Pressure was also monitored as PBS was pumped through 5, 6, and 7 mm long shunts at 
physiologically relevant flow rates of 50, 100, and 200 µL/h. Fluid flow studies 
demonstrated that resistance to flow increased with increased flow rate and increased shunt 
length (Figure 5.4.A-C). At each shunt length, there was a strong correlation between the 
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experimental measurements and theoretical pressure values predicted by the HPE. This 
correlation became stronger as shunt length, and therefore, entrance length increased. The 
percent difference between the slope of the linear trendline of experimental values and 
slope of the theoretical values was 22%, 8%, and 0%, respectively, for 5, 6, and 7 mm long 
shunts.  
 
5.3.4. IOP Reduction 
6 mm long PET shunts with either an open or closed lumen were implanted in normotensive 
rabbit eyes for 27 days via an ab externo procedure designed to vent aqueous humor via 
subconjunctival outflow. Procedure time ranged from 8-12 min for both types of shunts, 
and no complications were observed during the procedure or during the immediate post-
operative period. The lowest average IOP for rabbits with either open or closed PET shunts 
was observed 24 h post-operatively, indicating that the procedure itself may have 
contributed to IOP reduction in the immediate post-operative period (Figure 5.5.A-B). 
However, hypotony and flattening of the anterior chamber were not observed in the 
immediate, early, intermediate, or late post-operative period. The IOP of operated rabbit 
eyes containing closed PET shunts was not significantly different than that of the respective 
control contralateral eye. The decrease in IOP ranged from -4% to 25% on individual days 
following implantation, with the maximum decrease observed immediately post-
operatively. Operated rabbit eyes containing open PET shunts demonstrated a statistically 
significant decrease in IOP in comparison to the control contralateral eye. IOP reduction 
ranged from 24% to 57% on individual days following implantation. The IOP of operated 
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eyes containing open PET shunts was also significantly lower than that of operated eyes 
containing closed PET shunts. 
 
5.3.5. In Vivo Biocompatibility 
Nano-structured PET shunts were well-tolerated by rabbit eyes. Implanted shunts did not 
migrate into the anterior chamber during the course of the study, and there were no gross 
signs of infection, hyphema, or inflammation due to open or closed shunt implantation. 
Histological analysis of control subconjunctival tissue and tissue surrounding implanted 
shunts revealed the migration of cells to the periphery, and into the wall of PET shunts 
(Figure 5.6.A-C). Neovascularization was not observed in the immediate vicinity of either 
open or closed PET shunts. Notably, tissue sections also reveal that open PET shunts 
maintain their original inner and outer diameter (data not shown) for at least 27 days 




There is a need for glaucoma drainage devices with reduced post-operative complications, 
decreased reliance on ad hoc surgical “fixes,” and improved long-term outcomes. Here, we 
described the manufacture and evaluation of an electrospun tube shunt with dimensions 
derived from the HPE to preclude post-operative hypotony. Fluid flow through the 
nanofiber PET shunt obeys the HPE, and the shunt is strong, leak-proof, and durable. The 
shunt is biocompatible and significantly decreases IOP for at least 27 days in a 
normotensive rabbit model.  
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To our knowledge, this is the first study to utilize electrospinning in the manufacture of a 
glaucoma drainage implant.153,154 Electrospinning is a simple and versatile platform for the 
manufacture of medical devices. It is compatible with almost any natural or synthetic 
polymer, can incorporate prophylactic or therapeutic moieties, and be realized into a wide 
range of different morphologies or conformations.6,7 Devices manufactured via 
electrospinning are also highly modifiable through coatings, laser cutting, and other 
processing modifications to tune almost every aspect of the device, including size, shape, 
strength, rigidity, porosity, degradability, glidability, and biocompatibility. For example, 
nanofibers have been shown to demonstrate increased strength and decreased porosity in 
comparison to microfibers.103,155 In this study, the use of nanofibers to construct glaucoma 
shunts likely contributed to maintenance of an intact shunt lumen in vivo and prevention 
of leaking during flow studies in vitro. Heat treatment can be used to further increase shunt 
strength by aligning polymer chains and enhancing crystallinity, and if necessary, spray 
time can be modified to change wall thickness and modulate shunt flexibility.156  
 
Electrospinning and its versatility seem especially pertinent to the treatment of glaucoma 
with drainage devices, where the use of slightly inflammatory materials such as 
polypropylene can lead to device failure, and where scar formation and fibrosis cause 
significant complications.148,157 PET was chosen in this application because it is generally 
regarded as safe, has excellent biostability, a well-understood fibrotic response, and has 
been used in medical devices for over 50 years.158 However, should PET have not provided 
the appropriate strength, flexibility, or biological response, electrospinning permits facile 
interchange of polymer and/or modification of the manufacturing process to tailor the shunt 
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to fit the clinical need. Moreover, the capacity of electrospinning to manufacture nanofibers 
and incorporate them into a medical device, is a substantial advantage in glaucoma 
treatment. In their natural environment, cells interact with nanoscale architecture and cues 
within the surrounding extracellular matrix. These cues can affect cell migration, 
morphology, orientation, and even gene regulation. Kam and coworkers have demonstrated 
that nanoscale features with high aspect ratios decrease expression of several growth 
factors associated with fibrosis.8 Their experiments revealed that these features can also 
reduce protein adsorption, which has been implicated in glaucoma device fouling and can 
lead to infection, increase in IOP, or device failure.9 The methods used to manufacture 
marketed drainage devices, such as the iStent®, MicroShunt®, or XEN Gel Stent are limited 
in their capacity to achieve these effects through manufacturing alone.159 However, it is 
important to note that the porosity of nanofibrous devices make them vulnerable to cell 
and/or tissue ingrowth over the long-term.158  
 
While electrospinning may be a suitable platform for manufacture of glaucoma shunts, the 
safety and efficacy of shunts designed using HPE is still under investigation in humans. 
The XEN Gel Stent was also designed using the HPE, but is vulnerable to hypotony and 
anterior chamber shallowing in the immediate post-operative period at inner diameter 
dimensions of 63 or 140 µm.144 Due to the small lumen of the XEN Gel Stent with a 45 
µm inner diameter, fouling could theoretically affect its function over the long-term.149 
Venting resistance is inversely proportional to r4, thus, small variations in shunt diameter 
can have a considerable effect on venting IOP. Moreover, the HPE may not be able to 
accurately predict the performance of shunts in vivo, as the shunts are curved to suit ocular 
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anatomy. Additionally, in vitro fluid flow studies demonstrated that shorter PET shunts 
demonstrated a weaker correlation with the HPE. This may be due to the entrance length 
required to transition into stable, laminar flow, and is another factor to consider in the HPE-
driven design of glaucoma shunts.160   
 
Although the long-term efficacy of HPE-designed MIGS in humans is still under 
investigation, the performance of nano-structured PET shunts in healthy, normotensive 
rabbits in this study is promising. Open PET shunts maintained their inner diameter and 
significantly decreased IOP for at least 27 days in comparison to the non-operated 
contralateral eye. This is in stark contrast to previously conducted trabeculectomy and 
drainage implant procedures in healthy New Zealand White rabbits. Trabeculectomy 
procedures in these rabbits fail within 7 days without the use of an antifibrotic or 
antimetabolite agent.161 In a prospective, non-randomized study of fourteen patients, the 
MicroShunt® demonstrated a 49.8% reduction in IOP in conjunction mitomycin C after 3 
years; however, prior studies in New Zealand White rabbits demonstrated no significant 
change in IOP in comparison to non-operated eyes or to implantation of silicone tubing 
with an inner diameter of 300 µm.162,163 This suggests that open PET shunts may be able 
to vent significantly more aqueous humor in comparison to a healthy drainage system alone. 
Additional longer-term studies and studies in diseased animal models may help to better 








This study demonstrated the manufacture of a high strength, non-absorbable, minimally 
invasive glaucoma drainage implant via electrospinning. The shunt was designed through 
simulation of the HPE under physiological conditions in order to promote long-term IOP 
reduction while preventing hypotony. In vitro studies revealed that the PET shunt is leak-
proof and durable, and that fluid flow through the shunt behaves according to the HPE. In 
vivo experiments reveal that the shunt maintains its inner diameter and significantly 
decreases IOP for at least 27 days in normotensive rabbit eyes. This versatile fabrication 
platform could be used to manufacture next generation glaucoma shunts composed of 





























Figure 5.1. Model of pressure change through shunt. 
(A) Example shunt modeled using the HPE. (B) Change in pressure difference with change 
in shunt length at a flow rate of 150 µL/h. (C) Change in pressure difference with change 
in flow rate for a 50 µm diameter shunt. A 6 mm long shunt with a 50 µm diameter is 

















Figure 5.2. Manufacturing system and shunt design. 
(A) Schematic of electrospinning setup: high voltage is applied to the polymer solution 
which is then spun into a fiber coating around the template wire. (B) Design of PET shunt. 























Figure 5.3. PET shunt characterization. 
(A) Exterior of PET stent composed of nanofibers and revealing minimal porosity. (B) 
Cross-section of PET shunt with 50 µm diameter template wire and (C) cross-section 
without template wire. (D) Cross-section of PET shunt following one week of continuous 



















Figure 5.4. Theoretical and experimental pressure differential with flow of PBS 
through shunt. 



















Figure 5.5. IOP measurements in rabbits following implantation of either closed or 
open PET shunts. 
IOP was measured in both the operated and the contralateral control eyes of rabbits 
implanted with either a closed or open PET shunt. (A) Rabbit eyes implanted with a closed 
PET shunt demonstrated no significant change in IOP in comparison to the contralateral 
control eye (P = 0.08). (B) Rabbit eyes implanted with an open PET shunt demonstrated a 
significant decrease in IOP in comparison to the contralateral control eye (P < 0.0001). 
Rabbit eyes containing an open PET shunt demonstrated a significant decrease in IOP in 











Figure 5.6. Glaucoma shunt biocompatibility. 
Representative images of (A) untreated subconjunctival rabbit tissue, (B) tissue 
surrounding an implanted, open PET shunt, and (C) tissue surrounding an implanted, 
closed PET shunt following hematoxylin and eosin staining. The template wire became 



















The biological response to surgical/device intervention is a key leverage point for 
improvement of clinical outcomes in ocular and vascular surgery, and beyond. Thus, 
medical devices capable of directly modulating the local biological response without 
requiring systemic drug administration or a change to the surgical practice carry significant 
translational potential. We detailed the design, development, and evaluation of medical 
devices capable of modulating the post-operative biological response through 
nanotopography and/or drug delivery, while simultaneously serving their originally 
intended function.  
 
In Chapter 2, we describe the manufacture and evaluation of what is, to our knowledge, the 
first literature report of an antibiotic-loaded suture prepared by electrospinning at a 
diameter suitable for ocular surgery. Absorbable, antibiotic-eluting, monofilament sutures 
composed of PLLA, PEG, and levofloxacin were manufactured via wet electrospinning. 
Sutures provided sustained antibiotic release for more than 60 days in vitro, demonstrated 
activity against S. epidermidis for at least 1 week in vitro, and demonstrated similar 
biocompatibility to standard nylon sutures when implanted into rat corneas. However, the 
breaking strength of these sutures was below the minimum average breaking strength 
specified by the U.S.P. 
  
In Chapter 3, we hypothesized that by manufacturing hundreds of highly crystalline, drug-
loaded nanofibers and twisting them into a single multifilament suture, we could surpass 
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suture breaking strength requirements while also providing sufficient antibiotic delivery. 
To that end, we engineered a novel electrospinning system composed of two grounded 
collectors (one of which can rotate mechanically) positioned in parallel, allowing for 
deposition and twisting of nanofibers into a single, high strength, multifilament suture. 
Antibiotic-loaded, multifilament sutures manufactured using this platform met or exceeded 
U.S.P. specifications for size and strength suitable for ophthalmic use. To our knowledge, 
this is the first report of a drug-loaded suture with breaking strength surpassing U.S.P 
specifications. Further, no strength loss was observed when an equivalent amount of the 
levofloxacin used in the monofilament suture formulation in Chapter 2 was added to the 
multifilament suture formulation in Chapter 3. Multifilament sutures demonstrated 
biocompatibility comparable to conventional nylon sutures, and delivered levofloxacin at 
detectable levels in rat eyes for at least 14 days. Moreover, levofloxacin-eluting, 
multifilament sutures prevented ocular infection against consecutive bacterial inoculations 
for a period of 1 week in a rat model of bacterial keratitis. 
 
In Chapter 4, we utilized the manufacturing platform designed in Chapter 3 to coat 
conventional nylon sutures with drug-loaded, electrospun nanofibers in order to both 
surpass suture strength requirements and achieve sustained drug release. We established 
the uniformity of the nanofiber coating along the length of the suture and demonstrated 
tuning of rapamycin loading and release from nanofibers without compromising suture 
breaking strength. In addition, rapamycin-eluting, nanofiber-coated sutures demonstrated 
successful anastomosis of the rat abdominal aorta, and significantly reduced post-operative 
neointimal hyperplasia in comparison to a gold standard nylon suture. 
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In Chapter 5, we extended the use of the manufacturing platform described in Chapter 3 to 
the manufacture of medical devices other than sutures. We hypothesized that a nano-
structured, small lumen glaucoma drainage implant could significantly decrease intraocular 
pressure while also preventing hypotony. Nanofibrous glaucoma shunts were durable and 
leak-proof through extended periods of in vitro fluid flow, and fluid flow through the shunts 
behaved according to the Hagen-Poiseuille Equation. Moreover, shunts demonstrated 
biocompatibility and prevention of hypotony, and significantly decreased intraocular 
pressure in comparison to the contralateral control eye for at least 27 days when implanted 
into normotensive rabbits with the proximal end in the anterior chamber and the distal end 
in the subconjunctival space. This versatile fabrication platform could be used to 
manufacture next generation glaucoma shunts composed of almost any material and 
capable of additional functionality, including drug delivery, to improve glaucoma 
treatment. 
 
Collectively, the results described in this dissertation demonstrate the clinical potential of 
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